Advertisement

Cancer Pain

  • Jonathan Silverman
  • Amitabh Gulati
Chapter

Abstract

Pain is a ubiquitous part of the cancer experience. Whether disease-related, iatrogenic, or both, pain complicates all stages of disease and often persists despite curative treatment. Effective management of malignant pain requires an accurate diagnosis, rapid implementation of a multimodal treatment strategy, and frequent follow-up for rapid escalation if required. As treatment can include opioid and non-opioid pharmacotherapy, surgical and percutaneous interventions, psychotherapeutic techniques, manual therapies, and complementary/alternative medicine approaches, among others, multidisciplinary collaboration is often necessary. This chapter aims to introduce some of the most common strategies for managing oncologic pain and to discuss the data supporting their use.

Keywords

Cancer pain Pain management Analgesic ladder Interventional Complementary/alternative medicine 

References

  1. 1.
    Vendrell I, Macedo D, Alho I, Dionísio MR, Costa L. Treatment of cancer pain by targeting cytokines. Mediat Inflamm. 2015;2015:984570.CrossRefGoogle Scholar
  2. 2.
    Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer. 2002;2(3):201–9.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236–47.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Haumann J, Joosten EBA, Everdingen MHJVDB. Pain prevalence in cancer patients: status quo or opportunities for improvement? Curr Opin Support Palliat Care. 2017;11(2):99–104.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Centers for Medicare & Medicaid Services: Oncology Care Model; 2016. https://innovation.cms.gov/initiatives/oncology-care.
  6. 6.
    Loscalzo MJ. Palliative care: an historical perspective. Hematology Am Soc Hematol Educ Program. 2008;1:465.CrossRefGoogle Scholar
  7. 7.
    Chou R, Deyo RA, Jarvik JG. Appropriate use of lumbar imaging for evaluation of low back pain. Radiol Clin N Am. 2012;50(4):569–85.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Cuevas C, Shibata D. Medical imaging in the diagnosis and management of cancer pain. Curr Pain Headache Rep. 2009;13(4):261–70.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, Crowe J, Costello AJ. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016;42:56–72.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Trogdon JG, Chang Y, Shai S, Mucha PJ, Kuo TM, Meyer AM, Stitzenberg KB. Care coordination and multispecialty teams in the care of colorectal cancer patients. Med Care. 2018;56(5):430–5.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Licitra L, Keilholz U, Tahara M, Lin JC, Chomette P, Ceruse P, Harrington K, Mesia R. Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer. Oral Oncol. 2016;59:73–9.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30:1715–24.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Marks RM, Sachar EJ. Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med. 1973;78(2):173–81.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    World Health Organization. Cancer pain relief. Geneva: World Health Press; 1986.Google Scholar
  15. 15.
    Takeda F. The development of use of oral morphine within the last 10 years in Japan. Eur J Pain. 2001;5(Suppl A):79–82.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63(1):65–76.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician. 2010;56(6):514–7.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Carlson CL. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. J Pain Res. 2016;9:515–34.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol. 2016;34(5):436–42.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Fredheim OM, Brelin S, Hjermstad MJ, Loge JH, Aass N, Johannesen TB, Skurtveit S. Prescriptions of analgesics during complete disease trajectories in patients who are diagnosed with and die from cancer within the five-year period 2005–2009. Eur J Pain. 2017;21(3):530–40.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day R, Dougados M, Ehrich EW, Gijon-Baños J, Kvien TK, Van Rijswijk MH, Warner T, Zeidler H. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford). 1999;38(8):779–88.CrossRefGoogle Scholar
  22. 22.
    Oniga SD, Pacureanu L, Stoica CI, Palage MD, Crăciun A, Rusu LR, Crisan EL, Araniciu C. COX inhibition profile and molecular docking studies of some 2-(trimethoxyphenyl)-thiazoles. Molecules. 2017;22(9):E1507.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Venkat K, Brown MD, Barkin R. Nonsteroidal anti-inflammatory drugs and gastroduodenal injury. Am J Ther. 1998;5(4):263–72.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Delmas PD. Non-steroidal anti-inflammatory drugs and renal function. Br J Rheumatol. 1995;34(Suppl 1):25–8.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296(13):1619–32.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med Res Rev. 1996;16(2):181–206.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–9.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Walker C, Biasucci LM. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med. 2018;130(1):55–71.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Ross JS, Krumholz HM. Bringing Vioxx back to market. BMJ. 2018;360:k242.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–8.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Constance JE, Campbell SC, Somani AA, Yellepeddi V, Owens KH, Sherwin CMT. Pharmacokinetics, pharmacodynamics and pharmacogenetics associated with nonsteroidal anti-inflammatory drugs and opioids in pediatric cancer patients. Expert Opin Drug Metab Toxicol. 2017;13(7):715–24.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Armstrong P, Wilkinson P, McCorry NK. Use of parecoxib by continuous subcutaneous infusion for cancer pain in a hospice population. BMJ Support Palliat Care. 2018;8(1):25–9.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005;1:CD005180.Google Scholar
  34. 34.
    Strawson J. Nonsteroidal anti-inflammatory drugs and cancer pain. Curr Opin Support Palliat Care. 2018;12(2):102–7.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Cooper TE, Heathcote LC, Anderson B, Grégoire MC, Ljungman G, Eccleston C. Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents. Cochrane Database Syst Rev. 2017;7:CD012563.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Derry S, Wiffen PJ, Moore RA, McNicol ED, Bell RF, Carr DB, McIntyre M, Wee B. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017;7:CD012638.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Hooijmans CR, Geessink FJ, Ritskes-Hoitinga M, Scheffer GJ. A systematic review and meta-analysis of the ability of analgesic drugs to reduce metastasis in experimental cancer models. Pain. 2015;156(10):1835–44.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Grabosch SM, Shariff OM, Helm CW. Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2018;2:CD004121.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Lu Y, Liu XF, Liu TR, Fan RF, Xu YC, Zhang XZ, Liu LL. Celecoxib exerts antitumor effects in HL-60 acute leukemia cells and inhibits autophagy by affecting lysosome function. Biomed Pharmacother. 2016;84:1551–7.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Lu L, Shi L, Zeng J, Wen Z. Aspirin as a potential modality for the chemoprevention of breast cancer: a dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget. 2017;8(25):40389–401.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014;71(1):11–23.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Alloui A, Chassaing C, Schmidt J, Ardid D, Dubray C, Cloarec A, Eschalier A. Paracetamol exerts a spinal, tropisetron-reversible, antinociceptive effect in an inflammatory pain model in rats. Eur J Pharmacol. 2002;443(1–3):71–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Bujalska M. Effect of nitric oxide synthase inhibition on antinociceptive action of different doses of acetaminophen. Pol J Pharmacol. 2004;56(5):605–10.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Zygmunt PM, Ermund A, Movahed P, Andersson DA, Simonsen C, Jönsson BA, Blomgren A, Birnir B, Bevan S, Eschalier A, Mallet C, Gomis A, Högestätt ED. Monoacylglycerols activate TRPV1--a link between phospholipase C and TRPV1. PLoS One. 2013;8(12):e81618.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Hinz B, Brune K. Paracetamol and cyclooxygenase inhibition: is there a cause for concern? Ann Rheum Dis. 2012;71(1):20–5.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22(2):383–90.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum. 2006;54(1):282–91.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Wiffen PJ, Derry S, Moore RA, McNicol ED, Bell RF, Carr DB, McIntyre M, Wee B. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017;7:CD012637.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Israel FJ, Parker G, Charles M, Reymond L. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manag. 2010;39(3):548–54.CrossRefGoogle Scholar
  50. 50.
    Naito M, Sato T, Nakamura T, Yamanashi T, Miura H, Tsutsui A, Watanabe M. Pain management using acetaminophen throughout postoperative course of laparoscopic colorectal surgery: a case-matched control study. Ann Med Surg (Lond). 2017;17:38–42.CrossRefGoogle Scholar
  51. 51.
    Ohkura Y, Haruta S, Shindoh J, Tanaka T, Ueno M, Udagawa H. Effectiveness of postoperative intravenous acetaminophen (Acelio) after gastrectomy: a propensity score-matched analysis. Medicine (Baltimore). 2016;95(44):e5352.CrossRefGoogle Scholar
  52. 52.
    Artime CA, Aijazi H, Zhang H, Syed T, Cai C, Gumbert SD, Ferrario L, Normand KC, Williams GW, Hagberg CA. Scheduled intravenous acetaminophen improves patient satisfaction with postcraniotomy pain management: a prospective, randomized, placebo-controlled, double-blind study. J Neurosurg Anesthesiol. 2018;30(3):231–6.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Ohkura Y, Shindoh J, Ueno M, Iizuka T, Haruta S, Udagawa H. A new postoperative pain management (intravenous acetaminophen: Acelio®) leads to enhanced recovery after esophagectomy: a propensity score-matched analysis. Surg Today. 2018;48(5):502–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Amiri HR, Mirzaei M, Beig Mohammadi MT, Tavakoli F. Multi-modal preemptive analgesia with pregabalin, acetaminophen, naproxen, and dextromethorphan in radical neck dissection surgery: a randomized clinical trial. Anesth Pain Med. 2016;6(4):e33526.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Amiri HR, Mirzaei M, Pournaghi M, Fathi F. Three-agent preemptive analgesia, pregabalin-acetaminophen-naproxen, in laparotomy for cancer: a randomized clinical trial. Anesth Pain Med. 2016;7(2):e33269.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Mour G, Feinfeld DA, Caraccio T, McGuigan M. Acute renal dysfunction in acetaminophen poisoning. Ren Fail. 2005;27(4):381–3.PubMedCrossRefGoogle Scholar
  57. 57.
    Lee WM. Acetaminophen-related acute liver failure in the United States. Hepatol Res. 2008;38(Suppl 1):S3–8.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Bunchorntavakul C, Reddy KR. Acetaminophen (APAP or N-acetyl-p-aminophenol) and acute liver failure. Clin Liver Dis. 2018;22(2):325–46.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Faria J, Barbosa J, Moreira R, Queirós O, Carvalho F, Dinis-Oliveira RJ. Comparative pharmacology and toxicology of tramadol and tapentadol. Eur J Pain. 2018;22(5):827–44.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Kögel B, Schiene K, Straßburger W, Terlinden R, Tzschentke TM. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012;13(10):1437–49.PubMedCrossRefGoogle Scholar
  61. 61.
    Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017;5:CD012508.PubMedGoogle Scholar
  62. 62.
    O'Donnell JB, Ekman EF, Spalding WM, Bhadra P, McCabe D, Berger MF. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res. 2009;37(6):1789–802.PubMedCrossRefGoogle Scholar
  63. 63.
    Moore RA, McQuay HJ. Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain. 1997;69(3):287–94.PubMedCrossRefGoogle Scholar
  64. 64.
    Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC. Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analgesics. Drug Saf. 2018;41(8):787–95.PubMedCrossRefGoogle Scholar
  65. 65.
    Srinivas NR. Differential consequences of tramadol in overdosing: dilemma of a polymorphic cytochrome P450 2D6-mediated substrate. J Pain Palliat Care Pharmacother. 2015;29(3):272–5.PubMedCrossRefGoogle Scholar
  66. 66.
    No authors listed. “Weak” opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine. Prescrire Int. 2016;25(168):45–50.Google Scholar
  67. 67.
    Vicencio-Rosas E, Pérez-Guillé MG, Flores-Pérez C, Flores-Pérez J, Trujillo-Jiménez F, Chávez-Pacheco JL. Buprenorphine and pain treatment in pediatric patients: an update. J Pain Res. 2018;11:549–59.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115(6):1363–81.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Ondrovics M, Hoelbl-Kovacic A, Fux DA. Opioids: modulators of angiogenesis in wound healing and cancer. Oncotarget. 2017;8(15):25783–96.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Plein LM, Rittner HL. Opioids and the immune system - friend or foe. Br J Pharmacol. 2018;175(14):2717–25.PubMedCrossRefGoogle Scholar
  71. 71.
    Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–7.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Copenhaver DJ, Karvelas NB, Fishman SM. Risk management for opioid prescribing in the treatment of patients with pain from cancer or terminal illness: inadvertent oversight or taboo? Anesth Analg. 2017;125(5):1610–5.PubMedCrossRefGoogle Scholar
  73. 73.
    White LD, Hodge A, Vlok R, Hurtado G, Eastern K, Melhuish TM. Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2018;120(4):668–78.PubMedCrossRefGoogle Scholar
  74. 74.
    Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209–19.PubMedCrossRefGoogle Scholar
  75. 75.
    Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7:CD012592.PubMedGoogle Scholar
  76. 76.
    Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33(4):383–91.PubMedCrossRefGoogle Scholar
  77. 77.
    Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, Constine LS, Cooper A, Glare P, Keefe F, Koyyalagunta L, Levy M, Miaskowski C, Otis-Green S, Sloan P, Bruera E. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325–45.PubMedCrossRefGoogle Scholar
  78. 78.
    Beecher HK. Relationship of significance of wound to pain experienced. JAMA. 1956;161(17):1609–13.CrossRefGoogle Scholar
  79. 79.
    Hooten WM. Chronic pain and mental health disorders: shared neural mechanisms, epidemiology, and treatment. Mayo Clin Proc. 2016;91(7):955–70.PubMedCrossRefGoogle Scholar
  80. 80.
    Linden W, Vodermaier A, Mackenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141(2–3):343–51.PubMedCrossRefGoogle Scholar
  81. 81.
    Wasan AD, Michna E, Edwards RR, Katz JN, Nedeljkovic SS, Dolman AJ, Janfaza D, Isaac Z, Jamison RN. Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain. Anesthesiology. 2015;123(4):861–72.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40(11):1797–810.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain. 1992;49(2):205–19.PubMedCrossRefGoogle Scholar
  84. 84.
    Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosom Med. 1998;60(4):503–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci. 2017;18(11):E2483.PubMedCrossRefGoogle Scholar
  86. 86.
    Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Kimura M, Saito S, Obata H. Dexmedetomidine decreases hyperalgesia in neuropathic pain by increasing acetylcholine in the spinal cord. Neurosci Lett. 2012;529(1):70–4.PubMedCrossRefGoogle Scholar
  88. 88.
    Hiroki T, Suto T, Saito S, Obata H. Repeated administration of amitriptyline in neuropathic pain: modulation of the noradrenergic descending inhibitory system. Anesth Analg. 2017;125(4):1281–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain. 2007;8(4):315–24.PubMedCrossRefGoogle Scholar
  90. 90.
    Barygin OI, Nagaeva EI, Tikhonov DB, Belinskaya DA, Vanchakova NP, Shestakova NN. Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics. Brain Res. 1660;2017:58–66.Google Scholar
  91. 91.
    Yokogawa F, Kiuchi Y, Ishikawa Y, Otsuka N, Masuda Y, Oguchi K, Hosoyamada A. An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg. 2002;95(1):163–8.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Antkiewicz-Michaluk L, Romańska I, Michaluk J, Vetulani J. Role of calcium channels in effects of antidepressant drugs on responsiveness to pain. Psychopharmacology. 1991;105(2):269–74.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Galeotti N, Ghelardini C, Bartolini A. Involvement of potassium channels in amitriptyline and clomipramine analgesia. Neuropharmacology. 2001;40(1):75–84.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Phillis JW, Wu PH. Adenosine mediates sedative action of various centrally active drugs. Med Hypotheses. 1982;9(4):361–7.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    McCarson KE, Duric V, Reisman SA, Winter M, Enna SJ. GABA(B) receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants. Brain Res. 2006;1068(1):109–17.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Isenberg KE, Cicero TJ. Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. Eur J Pharmacol. 1984;103(1–2):57–63.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, Kuroda H, Nagamachi Y, Konuma Y, Fujimi A, Sagawa T, Ono K, Horiguchi H, Terui T, Koike K, Kusakabe T, Sato T, Takimoto R, Kobune M, Kato J. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol. 2015;20(5):866–71.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am J Health Syst Pharm. 2014;71(1):19–25.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Aziz MT, Good BL, Lowe DK. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann Pharmacother. 2014;48(5):626–32.PubMedCrossRefGoogle Scholar
  101. 101.
    Katsuyama S, Aso H, Otowa A, Yagi T, Kishikawa Y, Komatsu T, Sakurada T, Nakamura H. Antinociceptive effects of the serotonin and noradrenaline reuptake inhibitors milnacipran and duloxetine on vincristine-induced neuropathic pain model in mice. ISRN Pain. 2014;2014:915464.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5.PubMedCrossRefGoogle Scholar
  103. 103.
    Nishishinya B, Urrútia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, Darko G. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford). 2008;47(12):1741–6.CrossRefGoogle Scholar
  104. 104.
    Kaur S, Pandhi P, Dutta P. Painful diabetic neuropathy: an update. Ann Neurosci. 2011;18(4):168–75.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Kautio AL, Haanpää M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manag. 2008;35(1):31–9.CrossRefGoogle Scholar
  106. 106.
    Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, Tirona MT, Rowland KM Jr, Stella PJ, Johnson JA. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002;98(1–2):195–203.PubMedCrossRefGoogle Scholar
  107. 107.
    Kautio AL, Haanpää M, Leminen A, Kalso E, Kautiainen H, Saarto T. Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. Anticancer Res. 2009;29(7):2601–6.PubMedGoogle Scholar
  108. 108.
    Hughes S, Lacasse J, Fuller RR, Spaulding-Givens J. Adverse effects and treatment satisfaction among online users of four antidepressants. Psychiatry Res. 2017;255:78–86.PubMedCrossRefGoogle Scholar
  109. 109.
    Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697–706.PubMedCrossRefGoogle Scholar
  110. 110.
    Zygmunt M, Sapa J. Muscle relaxants--the current position in the treatment of spasticity in orthopedics. Ortop Traumatol Rehabil. 2015;17(4):423–30.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Patiño-Camacho SI, Déciga Campos M, Beltrán-Villalobos K, Castro-Vidal DA, Montiel-Ruiz RM, Flores-Murrieta FJ. Low doses of tizanidine synergize the anti-nociceptive and anti-inflammatory effects of ketorolac or naproxen while reducing of side effects. Eur J Pharmacol. 2017;805:51–7.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Lee S, Zhao X, Hatch M, Chun S, Chang E. Central neuropathic pain in spinal cord injury. Crit Rev Phys Rehabil Med. 2013;25(3–4):159–72.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Talakoub R, Abbasi S, Maghami E, Zavareh SM. The effect of oral tizanidine on postoperative pain relief after elective laparoscopic cholecystectomy. Adv Biomed Res. 2016;5:19.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Mastenbroek TC, Kramp-Hendriks BJ, Kallewaard JW, Vonk JM. Multimodal intrathecal analgesia in refractory cancer pain. Scand J Pain. 2017;14:39–43.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Kumru H, Kofler M, Flores MC, Portell E, Robles V, Leon N, Vidal J. Effect of intrathecal baclofen on evoked pain perception: an evoked potentials and quantitative thermal testing study. Eur J Pain. 2013;17(7):1039–47.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Nemeth BA, Montero RJ, Halanski MA, Noonan KJ. Epidural baclofen for the management of postoperative pain in children with cerebral palsy. J Pediatr Orthop. 2015;35(6):571–5.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Yenigün D, Ekiz T, Yuzer GF, Tasoglu O, Aslan MD, Ozgirgin N. Severe pain, spasticity, and heterotopic ossification in a patient with spinal cord injury: a vicious circle and management with baclofen pump. Pain Physician. 2014;17(6):E794–5.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Khurana SR, Garg DS. Spasticity and the use of intrathecal baclofen in patients with spinal cord injury. Phys Med Rehabil Clin N Am. 2014;25(3):655–9.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Pai A, Heining M. Ketamine. Continuing Educ Anaesth Crit Care Pain. 2007;7(2):59–63.CrossRefGoogle Scholar
  120. 120.
    Bredlau AL, Thakur R, Korones DN, Dworkin RH. Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med. 2013;14(10):1505–17.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2017;6:CD003351.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Fallon MT, Wilcock A, Kelly CA, Paul J, Lewsley LA, Norrie J, Laird BJA. Oral ketamine vs placebo in patients with cancer-related neuropathic pain: a randomized clinical trial. JAMA Oncol. 2018;4(6):870–2.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Kopsky DJ, Keppel Hesselink JM, Bhaskar A, Hariton G, Romanenko V, Casale R. Analgesic effects of topical ketamine. Minerva Anestesiol. 2015;81(4):440–9.PubMedPubMedCentralGoogle Scholar
  124. 124.
    Knezevic NN, Tverdohleb T, Nikibin F, Knezevic I, Candido KD. Management of chronic neuropathic pain with single and compounded topical analgesics. Pain Manag. 2017;7(6):537–58.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Singh V, Gillespie TW, Harvey RD. Intranasal ketamine and its potential role in cancer-related pain. Pharmacotherapy. 2018;38(3):390–401.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth. 1985;57(2):197–203.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    White PF, Way WL, Trevor AJ. Ketamine-its pharmacology and therapeutic uses. Anesthesiology. 1982;56(2):119–36.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Liebe T, Li S, Lord A, Colic L, Krause AL, Batra A, Kretzschmar MA, Sweeney-Reed CM, Behnisch G, Schott BH, Walter M. Factors influencing the cardiovascular response to subanesthetic ketamine: a randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2017;20(11):909–18.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Sener S, Eken C, Schultz CH, Serinken M, Ozsarac M. Ketamine with and without midazolam for emergency department sedation in adults: a randomized controlled trial. Ann Emerg Med. 2011;57(2):109–14.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, Patel SJ, Crysdale NY, Harrison JA, Maier SF, Rice KC, Watkins LR. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20–9.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Block L, Björklund U, Westerlund A, Jörneberg P, Biber B, Hansson E. A new concept affecting restoration of inflammation-reactive astrocytes. Neuroscience. 2013;250:536–45.PubMedCrossRefGoogle Scholar
  132. 132.
    Gold MS, Dackis CA, Pottash AL, Sternbach HH, Annitto WJ, Martin D, Dackis MP. Naltrexone, opiate addiction, and endorphins. Med Res Rev. 1982;2(3):211–46.PubMedCrossRefGoogle Scholar
  133. 133.
    Zagon IS, McLaughlin PJ. Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure. Brain Res Mol Brain Res. 1995;33(1):111–20.PubMedCrossRefGoogle Scholar
  134. 134.
    Paquette J, Olmstead MC. Ultra-low dose naltrexone enhances cannabinoid-induced antinociception. Behav Pharmacol. 2005;16(8):597–603.PubMedCrossRefGoogle Scholar
  135. 135.
    Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, Wu HL. A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol. 2006;48(9):1871–9.PubMedCrossRefGoogle Scholar
  136. 136.
    Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–9.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Ringerike T, Pike E, Nevjar J, Klemp M. The use of naltrexone in low doses beyond the approved indication. Research overview; 2015.Google Scholar
  138. 138.
    Raknes G, Småbrekke L. Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database. Pharmacoepidemiol Drug Saf. 2017;26(6):685–93.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–9.PubMedCrossRefGoogle Scholar
  140. 140.
    Liu WM, Scott KA, Dennis JL, Kaminska E, Levett AJ, Dalgleish AG. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: implications for its use in cancer therapy. Int J Oncol. 2016;49(2):793–802.PubMedCrossRefGoogle Scholar
  141. 141.
    Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood). 2011;236(7):883–95.CrossRefGoogle Scholar
  142. 142.
    Turel AP, Oh KH, Zagon IS, McLaughlin PJ. Low dose naltrexone for treatment of multiple sclerosis: a retrospective chart review of safety and tolerability. J Clin Psychopharmacol. 2015;35(5):609–11.PubMedCrossRefGoogle Scholar
  143. 143.
    Segal D, Macdonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2014;2:CD010410.Google Scholar
  144. 144.
    Mitchell JE. Naltrexone and hepatotoxicity. Lancet. 1986;1(8491):1215.PubMedCrossRefGoogle Scholar
  145. 145.
    Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. J Clin Gastroenterol. 2013;47(4):339–45.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Yen MH, Ko HC, Tang FI, Lu RB, Hong JS. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol. 2006;38(2):117–20.PubMedCrossRefGoogle Scholar
  147. 147.
    Adcock IM, Cosio B, Tsaprouni L, Barnes PJ, Ito K. Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response. Antioxid Redox Signal. 2005;7(1–2):144–52.PubMedCrossRefGoogle Scholar
  148. 148.
    Chow E, Loblaw A, Harris K, Doyle M, Goh P, Chiu H, Panzarella T, Tsao M, Barnes EA, Sinclair E, Farhadian M, Danjoux C. Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a pilot study. Support Care Cancer. 2007;15(6):643–7.PubMedCrossRefGoogle Scholar
  149. 149.
    Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. Neurooncol Pract. 2015;2(1):6–12.PubMedGoogle Scholar
  150. 150.
    Yang H, Seon J, Sung PS, Oh JS, Lee HL, Jang B, Chun HJ, Jang JW, Bae SH, Choi JY, Yoon SK. Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma: a randomized, double-blinded, placebo-controlled study. J Vasc Interv Radiol. 2017;28(11):1503–11.PubMedCrossRefGoogle Scholar
  151. 151.
    Haywood A, Good P, Khan S, Leupp A, Jenkins-Marsh S, Rickett K, Hardy JR. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database Syst Rev. 2015;4:CD010756.Google Scholar
  152. 152.
    Todd FD 2nd, Miller CA, Yates AJ, Mervis LJ. Steroid-induced remission in primary malignant lymphoma of the central nervous system. Surg Neurol. 1986;26(1):79–84.PubMedCrossRefGoogle Scholar
  153. 153.
    Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Kalkanis SN. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2010;96(1):103–14.CrossRefGoogle Scholar
  154. 154.
    Ly KI, Wen PY. Clinical relevance of steroid use in neuro-oncology. Curr Neurol Neurosci Rep. 2017;17(1):5.PubMedCrossRefGoogle Scholar
  155. 155.
    Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2011;4(2):233–42.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits ED. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med. 1984;311(9):549–52.PubMedCrossRefGoogle Scholar
  157. 157.
    Koehler PJ. Use of corticosteroids in neuro-oncology. Anti-Cancer Drugs. 1995;6(1):19–33.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Yang Q, Zhang Z, Xin W, Li A. Preoperative intravenous glucocorticoids can decrease acute pain and postoperative nausea and vomiting after total hip arthroplasty: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017;96(47):e8804.CrossRefGoogle Scholar
  159. 159.
    Clayburgh D, Stott W, Bolognone R, Palmer A, Achim V, Troob S, Li R, Brickman D, Graville D, Andersen P, Gross ND. A randomized controlled trial of corticosteroids for pain after transoral robotic surgery. Laryngoscope. 2017;127(11):2558–64.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, William W Jr, Pisters K, Eapen G, Fossella F, Amin S, Bruera E. Dexamethasone for dyspnea in cancer patients: a pilot double-blind, randomized, controlled trial. J Pain Symptom Manage. 2016;52(1):8–16.PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. Arch Dis Child. 2016;101(4):365–70.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Ravindran V, Rachapalli S, Choy EH. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford). 2009;48(7):807–11.CrossRefGoogle Scholar
  163. 163.
    Alles SRA, Smith PA. Etiology and pharmacology of neuropathic pain. Pharmacol Rev. 2018;70(2):315–47.PubMedPubMedCentralCrossRefGoogle Scholar
  164. 164.
    Chen J, Li L, Chen SR, Chen H, Xie JD, Sirrieh RE, MacLean DM, Zhang Y, Zhou MH, Jayaraman V, Pan HL. The α2δ-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions. Cell Rep. 2018;22(9):2307–21.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY, North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110–8.PubMedCrossRefGoogle Scholar
  166. 166.
    Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010;30(7):2927–33.PubMedGoogle Scholar
  167. 167.
    Heir GM, Masterson M. Bilateral glossopharyngeal neuropathy following chemo and radiation therapy for a primitive neuroectodermal tumour. J Oral Rehabil. 2016;43(2):154–8.PubMedCrossRefGoogle Scholar
  168. 168.
    Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. Curr Opin Support Palliat Care. 2018;12(2):108–17.PubMedGoogle Scholar
  169. 169.
    Doleman B, Heinink TP, Read DJ, Faleiro RJ, Lund JN, Williams JP. A systematic review and meta-regression analysis of prophylactic gabapentin for postoperative pain. Anaesthesia. 2015;70(10):1186–204.PubMedCrossRefGoogle Scholar
  170. 170.
    Zencirci B. Analgesic efficacy of oral gabapentin added to standard epidural corticosteroids in patients with failed back surgery. Clin Pharmacol. 2010;2:207–11.PubMedPubMedCentralGoogle Scholar
  171. 171.
    Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist. 2005;70(144):43633–5.Google Scholar
  172. 172.
    Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, Schneeweiss S. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303(14):1401–9.PubMedCrossRefGoogle Scholar
  173. 173.
    Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4):236–41.PubMedPubMedCentralCrossRefGoogle Scholar
  174. 174.
    Matsushita Y, Araki K, Omotuyi OI, Mukae T, Ueda H. HDAC inhibitors restore C-fibre sensitivity in experimental neuropathic pain model. Br J Pharmacol. 2013;170(5):991–8.PubMedPubMedCentralCrossRefGoogle Scholar
  175. 175.
    Rodriguez-Menendez V, Gilardini A, Bossi M, Canta A, Oggioni N, Carozzi V, Tremolizzo L, Cavaletti G. Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res. 2008;28(1A):335–42.PubMedPubMedCentralGoogle Scholar
  176. 176.
    Wadia RJ, Stolar M, Grens C, Ehrlich BE, Chao HH. The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget. 2017;9(7):7322–31.PubMedPubMedCentralGoogle Scholar
  177. 177.
    Rauck R, Busch M, Marriott T. Effectiveness of a heated lidocaine/tetracaine topical patch for pain associated with myofascial trigger points: results of an open-label pilot study. Pain Pract. 2013;13(7):533–8.PubMedCrossRefPubMedCentralGoogle Scholar
  178. 178.
    Cheng YJ. Lidocaine skin patch (Lidopat® 5%) is effective in the treatment of traumatic rib fractures: a prospective double-blinded and vehicle-controlled study. Med Princ Pract. 2016;25(1):36–9.PubMedCrossRefPubMedCentralGoogle Scholar
  179. 179.
    van den Heuvel SAS, van der Wal SEI, Smedes LA, Radema SA, van Alfen N, Vissers KCP, Steegers MAH. Intravenous lidocaine: old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy. Pain Res Manag. 2017;2017:8053474.PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Ho MLJ, Kerr SJ, Stevens J. Intravenous lidocaine infusions for 48 hours in open colorectal surgery: a prospective, randomized, double-blinded, placebo-controlled trial. Korean J Anesthesiol. 2018;71(1):57–65.PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Kamei J, Nozaki C, Saitoh A. Effect of mexiletine on vincristine-induced painful neuropathy in mice. Eur J Pharmacol. 2006;536(1–2):123–7.PubMedCrossRefPubMedCentralGoogle Scholar
  182. 182.
    Egashira N, Hirakawa S, Kawashiri T, Yano T, Ikesue H, Oishi R. Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. J Pharmacol Sci. 2010;112(4):473–6.PubMedCrossRefPubMedCentralGoogle Scholar
  183. 183.
    Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67(12):2253–5.PubMedCrossRefPubMedCentralGoogle Scholar
  184. 184.
    von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, Obermeier F, Erdmann J, Schmelz R, Quasthoff S, Adelsberger H, Bredenkamp R, Schmid RM, Lersch C. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Investig New Drugs. 2007;25(2):173–80.CrossRefGoogle Scholar
  185. 185.
    Carroll IR, Kaplan KM, Mackey SC. Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success. J Pain Symptom Manag. 2008;35(3):321–6.CrossRefGoogle Scholar
  186. 186.
    Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther. 2011;90(3):377–87.PubMedCrossRefPubMedCentralGoogle Scholar
  187. 187.
    Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19(12):1985–91.PubMedPubMedCentralCrossRefGoogle Scholar
  188. 188.
    Gulati A, Shah R, Puttanniah V, Hung J, Malhotra V. A retrospective review and treatment paradigm of interventional therapies for patients suffering from intractable thoracic chest wall pain in the oncologic population. Pain Med. 2015;16(4):802–10.PubMedCrossRefPubMedCentralGoogle Scholar
  189. 189.
    Hutson N, Hung J, Puttanniah V, Lis E, Laufer I, Gulati A. Interventional pain management for sacroiliac tumors in the oncologic population: a case series and paradigm approach. Pain Med. 2016;18(5):959–68.PubMedCentralGoogle Scholar
  190. 190.
    Neal JM. Ultrasound-guided regional anesthesia and patient safety: update of an evidence-based analysis. Reg Anesth Pain Med. 2016;41(2):195–204.PubMedCrossRefPubMedCentralGoogle Scholar
  191. 191.
    McDermott G, Korba E, Mata U, Jaigirdar M, Narayanan N, Boylan J, Conlon N. Should we stop doing blind transversus abdominis plane blocks? Br J Anaesth. 2012;108(3):499–502.PubMedCrossRefPubMedCentralGoogle Scholar
  192. 192.
    Nader A, Kendall MC, De Oliveria GS, Chen JQ, Vanderby B, Rosenow JM, Bendok BR. Ultrasound-guided trigeminal nerve block via the pterygopalatine fossa: an effective treatment for trigeminal neuralgia and atypical facial pain. Pain Physician. 2013;16(5):E537–45.PubMedPubMedCentralGoogle Scholar
  193. 193.
    Siegenthaler A, Moriggl B, Mlekusch S, Schliessbach J, Haug M, Curatolo M, Eichenberger U. Ultrasound-guided suprascapular nerve block, description of a novel supraclavicular approach. Reg Anesth Pain Med. 2012;37(3):325–8.PubMedCrossRefPubMedCentralGoogle Scholar
  194. 194.
    Wijayasinghe N, Duriaud HM, Kehlet H, Andersen KG. Ultrasound guided intercostobrachial nerve blockade in patients with persistent pain after breast cancer surgery: a pilot study. Pain Physician. 2016;19(2):E309–18.PubMedPubMedCentralGoogle Scholar
  195. 195.
    Wisotzky E, Saini V, Kao C. Ultrasound-guided intercostobrachial nerve block for intercostobrachial neuralgia in breast cancer patients: a case series. PM R. 2016;8(3):273–7.PubMedCrossRefPubMedCentralGoogle Scholar
  196. 196.
    Thomassen I, van Suijlekom JA, van de Gaag A, Ponten JE, Nienhuijs SW. Ultrasound-guided ilioinguinal/iliohypogastric nerve blocks for chronic pain after inguinal hernia repair. Hernia. 2013;17(3):329–32.PubMedCrossRefPubMedCentralGoogle Scholar
  197. 197.
    Hong M, Kim Y, Park J, Hong H. Management of pudendal neuralgia using ultrasound-guided pulsed radiofrequency: a report of two cases and discussion of pudendal nerve block techniques. J Anesth. 2015;30(2):356–9.PubMedCrossRefGoogle Scholar
  198. 198.
    Saranteas T, Anagnostis G, Paraskeuopoulos T, Koulalis D, Kokkalis Z, Nakou M, Anagnostopoulou S, Kostopanagiotou G. Anatomy and clinical implications of the ultrasound-guided subsartorial saphenous nerve block. Reg Anesth Pain Med. 2011;36(4):399–402.PubMedCrossRefGoogle Scholar
  199. 199.
    Malik T. Ultrasound-guided paravertebral neurolytic block: a report of two cases. Pain Pract. 2013;14(4):346–9.PubMedCrossRefGoogle Scholar
  200. 200.
    Blanco R, Parras T, McDonnell JG, Prats-Galino A. Serratus plane block: a novel ultrasound-guided thoracic wall nerve block. Anaesthesia. 2013;68(11):1107–13.PubMedCrossRefGoogle Scholar
  201. 201.
    Zocca JA, Chen GH, Puttanniah VG, Hung JC, Gulati A. Ultrasound-guided serratus plane block for treatment of postmastectomy pain syndromes in breast cancer patients: a case series. Pain Pract. 2017;17(1):141–6.PubMedCrossRefGoogle Scholar
  202. 202.
    Piracha MM, Thorp SL, Puttanniah V, Gulati A. “A tale of two planes”: deep versus superficial serratus plane block for postmastectomy pain syndrome. Reg Anesth Pain Med. 2017;42(2):259–62.PubMedCrossRefGoogle Scholar
  203. 203.
    Abdallah FW, MacLean D, Madjdpour C, Cil T, Bhatia A, Brull R. Pectoralis and serratus fascial plane blocks each provide early analgesic benefits following ambulatory breast cancer surgery: a retrospective propensity-matched cohort study. Anesth Analg. 2017;125(1):294–302.PubMedCrossRefGoogle Scholar
  204. 204.
    Hebbard PD, Barrington MJ, Vasey C. Ultrasound-guided continuous oblique subcostal transversus abdominis plane blockade: description of anatomy and clinical technique. Reg Anesth Pain Med. 2010;35(5):436–41.PubMedCrossRefGoogle Scholar
  205. 205.
    Blomstedt PC, Bergenheim AT. Technical difficulties and perioperative complications of retrogasserian glycerol rhizotomy for trigeminal neuralgia. Stereotact Funct Neurosurg. 2002;79(3–4):168–81.PubMedCrossRefPubMedCentralGoogle Scholar
  206. 206.
    Ischia S, Luzzani A, Polati E, Ischia A. Percutaneous controlled thermocoagulation in the treatment of trigeminal neuralgia. Clin J Pain. 1990;6(2):96–104.PubMedCrossRefPubMedCentralGoogle Scholar
  207. 207.
    Gunduz OH, Kenis-Coskun O. Ganglion blocks as a treatment of pain: current perspectives. J Pain Res. 2017;10:2815–26.PubMedPubMedCentralCrossRefGoogle Scholar
  208. 208.
    Pather N, Partab P, Singh B, Satyapal KS. Cervico-thoracic ganglion: its clinical implications. Clin Anat. 2006;19(4):323–6.PubMedCrossRefPubMedCentralGoogle Scholar
  209. 209.
    Ghai A, Kaushik T, Kumar R, Wadhera S. Chemical ablation of stellate ganglion for head and neck cancer pain. Acta Anaesthesiol Belg. 2016;67(1):6–8.PubMedGoogle Scholar
  210. 210.
    Guo JR, Guo W, Jin XJ, Yu J, Jin BW, Xu F, Liu Y. Effects of stellate ganglionic block on hemodynamic changes and intrapulmonary shunt in perioperative patients with esophageal cancer. Eur Rev Med Pharmacol Sci. 2014;18(24):3864–9.PubMedPubMedCentralGoogle Scholar
  211. 211.
    Park JH, Min YS, Chun SM, Seo KS. Effects of stellate ganglion block on breast cancer-related lymphedema: comparison of various injectates. Pain Physician. 2015;18(1):93–9.PubMedPubMedCentralGoogle Scholar
  212. 212.
    Kambadakone A, Thabet A, Gervais DA, Mueller PR, Arellano RS. CT-guided celiac plexus neurolysis: a review of anatomy, indications, technique, and tips for successful treatment. Radiographics. 2011;31(6):1599–621.PubMedCrossRefPubMedCentralGoogle Scholar
  213. 213.
    Cao J, He Y, Liu H, Wang S, Zhao B, Zheng X, Yang K, Xie D. Effectiveness of percutaneous celiac plexus ablation in the treatment of severe cancer pain in upper abdomen and evaluation of health economics. Am J Hosp Palliat Care. 2017;34(2):142–7.PubMedCrossRefPubMedCentralGoogle Scholar
  214. 214.
    Shwita AH, Amr YM, Okab MI. Comparative study of the effects of the retrocrural celiac plexus block versus splanchnic nerve block, C-arm guided, for upper gastrointestinal tract tumors on pain relief and the quality of life at a six-month follow up. Korean J Pain. 2015;28(1):22–31.PubMedPubMedCentralCrossRefGoogle Scholar
  215. 215.
    Nitschke AM, Ray CE Jr. Percutaneous neurolytic celiac plexus block. Semin Intervent Radiol. 2013;30(3):318–21.PubMedPubMedCentralCrossRefGoogle Scholar
  216. 216.
    Seicean A. Celiac plexus neurolysis in pancreatic cancer: the endoscopic ultrasound approach. World J Gastroenterol. 2014;20(1):110–7.PubMedPubMedCentralCrossRefGoogle Scholar
  217. 217.
    Koyyalagunta D, Engle MP, Yu J, Feng L, Novy DM. The effectiveness of alcohol versus phenol based splanchnic nerve neurolysis for the treatment of intra-abdominal cancer pain. Pain Physician. 2016;19(4):281–92.PubMedPubMedCentralGoogle Scholar
  218. 218.
    Staats PS, Hekmat H, Sauter P, Lillemoe K. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study. Pain Med. 2001;2(1):28–34.PubMedCrossRefPubMedCentralGoogle Scholar
  219. 219.
    Fujii-Lau LL, Bamlet WR, Eldrige JS, Chari ST, Gleeson FC, Abu Dayyeh BK, Clain JE, Pearson RK, Petersen BT, Rajan E, Topazian MD, Vege SS, Wang KK, Wiersema MJ, Levy MJ. Impact of celiac neurolysis on survival in patients with pancreatic cancer. Gastrointest Endosc. 2015;82(1):46–56.PubMedPubMedCentralCrossRefGoogle Scholar
  220. 220.
    Oh TK, Lee WJ, Woo SM, Kim NW, Yim J, Kim DH. Impact of celiac plexus neurolysis on survival in patients with unresectable pancreatic cancer: a retrospective, propensity score matching analysis. Pain Physician. 2017;20(3):E357–65.PubMedGoogle Scholar
  221. 221.
    Minaga K, Kitano M, Imai H, Miyata T, Kudo M. Acute spinal cord infarction after EUS-guided celiac plexus neurolysis. Gastrointest Endosc. 2016;83(5):1039–40.PubMedCrossRefGoogle Scholar
  222. 222.
    Koker IH, Aralasmak A, Unver N, Asil T, Senturk H. Spinal cord ischemia after endoscopic ultrasound guided celiac plexus neurolysis: case report and review of the literature. Scand J Gastroenterol. 2017;52(10):1158–61.PubMedCrossRefGoogle Scholar
  223. 223.
    Heindel W, Ernst S, Manshausen G, Gawenda M, Siemens P, Krahe T, Walter M, Lackner K. CT-guided lumbar sympathectomy: results and analysis of factors influencing the outcome. Cardiovasc Intervent Radiol. 1998;21(4):319–23.PubMedCrossRefGoogle Scholar
  224. 224.
    Sze DY, Mackey SC. MR guidance of sympathetic nerve blockade: measurement of vasomotor response initial experience in seven patients. Radiology. 2002;223(2):574–80.PubMedCrossRefGoogle Scholar
  225. 225.
    Hong JH, Oh MJ. Comparison of multilevel with single level injection during lumbar sympathetic ganglion block: efficacy of sympatholysis and incidence of psoas muscle injection. Korean J Pain. 2010;23(2):131–6.PubMedPubMedCentralCrossRefGoogle Scholar
  226. 226.
    Abramov R. Lumbar sympathetic treatment in the management of lower limb pain. Curr Pain Headache Rep. 2014;18(4):403.PubMedCrossRefGoogle Scholar
  227. 227.
    Carroll I, Clark JD, Mackey S. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann Neurol. 2009;65(3):348–51.PubMedPubMedCentralCrossRefGoogle Scholar
  228. 228.
    Feigl GC, Dreu M, Ulz H, Breschan C, Maier C, Likar R. Susceptibility of the genitofemoral and lateral femoral cutaneous nerves to complications from lumbar sympathetic blocks: is there a morphological reason? Br J Anaesth. 2014;112(6):1098–104.PubMedCrossRefGoogle Scholar
  229. 229.
    Sniderman M, Raghavendra M, Holtman JR Jr. Priapism following a lumbar sympathetic nerve block. Pain Med. 2011;12(7):1046–8.PubMedCrossRefGoogle Scholar
  230. 230.
    Dirim A, Kumsar S. Iatrogenic ureteral injury due to lumbar sympathetic block. Scand J Urol Nephrol. 2008;42(4):395–6.PubMedCrossRefPubMedCentralGoogle Scholar
  231. 231.
    Kraima AC, van Schaik J, Susan S, van de Velde CJ, Hamming JF, Lakke EA, DeRuiter MC. New insights in the neuroanatomy of the human adult superior hypogastric plexus and hypogastric nerves. Auton Neurosci. 2015;189:60–7.PubMedCrossRefPubMedCentralGoogle Scholar
  232. 232.
    Plancarte R, Amescua C, Patt RB, Aldrete JA. Superior hypogastric plexus block for pelvic cancer pain. Anesthesiology. 1990;73(2):236–9.PubMedCrossRefPubMedCentralGoogle Scholar
  233. 233.
    Cariati M, De Martini G, Pretolesi F, Roy MT. CT-guided superior hypogastric plexus block. J Comput Assist Tomogr. 2002;26(3):428–31.PubMedCrossRefPubMedCentralGoogle Scholar
  234. 234.
    Turker G, Basagan-Mogol E, Gurbet A, Ozturk C, Uckunkaya N, Sahin S. A new technique for superior hypogastric plexus block: the posteromedian transdiscal approach. Tohoku J Exp Med. 2005;206(3):277–81.PubMedCrossRefPubMedCentralGoogle Scholar
  235. 235.
    Mishra S, Bhatnagar S, Gupta D, Thulkar S. Anterior ultrasound-guided superior hypogastric plexus neurolysis in pelvic cancer pain. Anaesth Intensive Care. 2008;36(5):732–5.PubMedCrossRefPubMedCentralGoogle Scholar
  236. 236.
    de Leon-Casasola OA, Kent E, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Pain. 1993;54(2):145–51.PubMedCrossRefPubMedCentralGoogle Scholar
  237. 237.
    Scott-Warren JT, Hill V, Rajasekaran A. Ganglion impar blockade: a review. Curr Pain Headache Rep. 2013;17(1):306.PubMedCrossRefPubMedCentralGoogle Scholar
  238. 238.
    Foye PM. Ganglion impar blocks via coccygeal versus sacrococcygeal joints. Reg Anesth Pain Med. 2008;33(3):279–80.PubMedCrossRefPubMedCentralGoogle Scholar
  239. 239.
    Huang JJ. Another modified approach to the ganglion of Walther block (ganglion of impar). J Clin Anesth. 2003;15(4):282–3.PubMedCrossRefPubMedCentralGoogle Scholar
  240. 240.
    Agarwal-Kozlowski K, Lorke DE, Habermann CR, Am Esch JS, Beck H. CT-guided blocks and neuroablation of the ganglion impar (Walther) in perineal pain: anatomy, technique, safety, and efficacy. Clin J Pain. 2009;25(7):570–6.PubMedCrossRefPubMedCentralGoogle Scholar
  241. 241.
    Lin CS, Cheng JK, Hsu YW, Chen CC, Lao HC, Huang CJ, Cheng PH, Narouze S. Ultrasound-guided ganglion impar block: a technical report. Pain Med. 2010;11(3):390–4.PubMedCrossRefPubMedCentralGoogle Scholar
  242. 242.
    Marker DR, U-Thainual P, Ungi T, Flammang AJ, Fichtinger G, Iordachita II, Carrino JA, Fritz J. MR-guided perineural injection of the ganglion impar: technical considerations and feasibility. Skelet Radiol. 2016;45(5):591–7.CrossRefGoogle Scholar
  243. 243.
    Gunduz OH, Sencan S, Kenis-Coskun O. Pain relief due to transsacrococcygeal ganglion impar block in chronic coccygodynia: a pilot study. Pain Med. 2015;16(7):1278–81.PubMedCrossRefPubMedCentralGoogle Scholar
  244. 244.
    Adas C, Ozdemir U, Toman H, Luleci N, Luleci E, Adas H. Transsacrococcygeal approach to ganglion impar: radiofrequency application for the treatment of chronic intractable coccydynia. J Pain Res. 2016;9:1173–7.PubMedPubMedCentralCrossRefGoogle Scholar
  245. 245.
    McCormick Z, Kennedy DJ, Garvan C, Rivers E, Temme K, Margolis S, Zander E, Rohr A, Smith MC, Plastaras C. Comparison of pain score reduction using triamcinolone vs. betamethasone in transforaminal epidural steroid injections for lumbosacral radicular pain. Am J Phys Med Rehabil. 2015;94(12):1058–64.PubMedCrossRefPubMedCentralGoogle Scholar
  246. 246.
    Kennedy DJ, Plastaras C, Casey E, Visco CJ, Rittenberg JD, Conrad B, Sigler J, Dreyfuss P. Comparative effectiveness of lumbar transforaminal epidural steroid injections with particulate versus nonparticulate corticosteroids for lumbar radicular pain due to intervertebral disc herniation: a prospective, randomized, double-blind trial. Pain Med. 2014;15(4):548–55.PubMedCrossRefPubMedCentralGoogle Scholar
  247. 247.
    Ploumis A, Christodoulou P, Wood KB, Varvarousis D, Sarni JL, Beris A. Caudal vs transforaminal epidural steroid injections as short-term (6 months) pain relief in lumbar spinal stenosis patients with sciatica. Pain Med. 2014;15(3):379–85.PubMedCrossRefPubMedCentralGoogle Scholar
  248. 248.
    Wei G, Liang J, Chen B, Zhou C, Ru N, Chen J, Zhang F. Comparison of transforaminal verse interlaminar epidural steroid injection in low back pain with lumbosacral radicular pain: a meta-analysis of the literature. Int Orthop. 2016;40(12):2533–45.PubMedCrossRefPubMedCentralGoogle Scholar
  249. 249.
    Beyaz SG. Comparison of transforaminal and interlaminar epidural steroid injections for the treatment of chronic lumbar pain. Braz J Anesthesiol. 2017;67(1):21–7.PubMedCrossRefPubMedCentralGoogle Scholar
  250. 250.
    El-Yahchouchi CA, Plastaras CT, Maus TP, Carr CM, McCormick ZL, Geske JR, Smuck M, Pingree MJ, Kennedy DJ. Adverse event rates associated with transforaminal and interlaminar epidural steroid injections: a multi-institutional study. Pain Med. 2016;17(2):239–49.PubMedPubMedCentralGoogle Scholar
  251. 251.
    Ertas IE, Sehirali S, Ozsezgin Ocek S, Sanci M, Arbak G, Yildirim Y. The effectiveness of subcutaneously implanted epidural ports for relief of severe pain in patients with advanced-stage gynecological cancer: a prospective study. Agri. 2014;26(1):8–14.PubMedCrossRefPubMedCentralGoogle Scholar
  252. 252.
    van Boekel RL, Vissers KC, van de Vossenberg G, de Baat-Ananta M, van der Sande R, Scheffer GJ, Steegers MA. Comparison of epidural or regional analgesia and patient-controlled analgesia: a critical analysis of patient data by the acute pain service in a university hospital. Clin J Pain. 2016;32(8):681–8.PubMedCrossRefGoogle Scholar
  253. 253.
    Candido K, Stevens RA. Intrathecal neurolytic blocks for the relief of cancer pain. Best Pract Res Clin Anaesthesiol. 2003;17(3):407–28.PubMedCrossRefPubMedCentralGoogle Scholar
  254. 254.
    Hay C. Subarachnoid alcohol block in the control of intractable pain: report of results in 252 patients. Anesth Analg. 1962;41:12–6.PubMedCrossRefGoogle Scholar
  255. 255.
    Wood KM. The use of phenol as a neurolytic agent: a review. Pain. 1978;5(3):205–29.PubMedCrossRefGoogle Scholar
  256. 256.
    Heavner JE, Racz GB. Gross and microscopic lesions produced by phenol neurolytic procedures. In: Racz GB, editor. Techniques of neurolysis. Boston: Kluwer Academic; 1989. p. 27–33.CrossRefGoogle Scholar
  257. 257.
    Xie W, Strong JA, Zhang JM. Active nerve regeneration with failed target reinnervation drives persistent neuropathic pain. eNeuro. 2017;4(1)PubMedPubMedCentralCrossRefGoogle Scholar
  258. 258.
    Deer TR, Smith HS, Cousins M, Doleys DM, Levy RM, Rathmell JP, Staats PS, Wallace M, Webster LR. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician. 2010;13(3):E175–213.PubMedGoogle Scholar
  259. 259.
    Burton AW, Conroy B, Garcia E, Solanki D, Williams CG. Illicit substance abuse via an implanted intrathecal pump. Anesthesiology. 1998;89(5):1264–7.PubMedCrossRefGoogle Scholar
  260. 260.
    Gebhardt R, Ludwig M, Kirsner S, Kisling K, Kosturakis AK. Implanted intrathecal drug delivery systems and radiation treatment. Pain Med. 2013;14(3):398–402.PubMedCrossRefGoogle Scholar
  261. 261.
    Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Català E, Bryce DA, Coyne PJ, Pool GE, Implantable Drug Delivery Systems Study Group. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040–9.PubMedCrossRefGoogle Scholar
  262. 262.
    Deer TR, Pope JE, Hayek SM, Bux A, Buchser E, Eldabe S, De Andrés JA, Erdek M, Patin D, Grider JS, Doleys DM, Jacobs MS, Yaksh TL, Poree L, Wallace MS, Prager J, Rauck R, DeLeon O, Diwan S, Falowski SM, Gazelka HM, Kim P, Leong M, Levy RM, McDowell G II, McRoberts P, Naidu R, Narouze S, Perruchoud C, Rosen SM, Rosenberg WS, Saulino M, Staats P, Stearns LJ, Willis D, Krames E, Huntoon M, Mekhail N. The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20(2):96–132.PubMedCrossRefGoogle Scholar
  263. 263.
    McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol. 1997;30(3):400–3.PubMedCrossRefGoogle Scholar
  264. 264.
    Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, Fisher R, Bryce DA, Mangieri EA, Luther RR, Mayo M, McGuire D, Ellis D. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291(1):63–70.PubMedCrossRefGoogle Scholar
  265. 265.
    Wallace MS, Rauck RL, Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain. 2010;26(7):635–44.PubMedCrossRefGoogle Scholar
  266. 266.
    Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures containing ziconotide 25 mcg/mL and morphine sulfate 10 mg/mL or 20 mg/mL during simulated Intrathecal administration. Int J Pharm Compd. 2008;12(6):553–7.PubMedGoogle Scholar
  267. 267.
    Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. Int J Pharm Compd. 2008;12(5):463–6.PubMedGoogle Scholar
  268. 268.
    Robert J, Sorrieul J, Rossignol E, Beaussart H, Kieffer H, Folliard C, Dupoiron D, Devys C. Chemical stability of morphine, ropivacaine, and ziconotide in combination for intrathecal analgesia. Int J Pharm Compd. 2017;21(4):347–51.PubMedGoogle Scholar
  269. 269.
    Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63–70.PubMedCrossRefGoogle Scholar
  270. 270.
    Hettiarachchi HD, Hsu Y, Harris TJ Jr, Penn R, Linninger AA. The effect of pulsatile flow on intrathecal drug delivery in the spinal canal. Ann Biomed Eng. 2011;39(10):2592–602.PubMedCrossRefGoogle Scholar
  271. 271.
    Hsu Y, Hettiarachchi HD, Zhu DC, Linninger AA. The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth Analg. 2012;115(2):386–94.PubMedCrossRefGoogle Scholar
  272. 272.
    Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105(1):169–78.PubMedCrossRefGoogle Scholar
  273. 273.
    Wallace M, Yaksh TL. Characteristics of distribution of morphine and metabolites in cerebrospinal fluid and plasma with chronic intrathecal morphine infusion in humans. Anesth Analg. 2012;115(4):797–804.PubMedPubMedCentralCrossRefGoogle Scholar
  274. 274.
    Tangen KM, Hsu Y, Zhu DC, Linninger AA. CNS wide simulation of flow resistance and drug transport due to spinal microanatomy. J Biomech. 2015;48(10):2144–54.PubMedCrossRefGoogle Scholar
  275. 275.
    Sigg J, Sonntag JC, Li J. Solubility and stability of intrathecal baclofen solutions at high concentrations: implications for chronic use in the SynchroMed VR infusion system; 2009.Google Scholar
  276. 276.
    Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, Caraway D, Cousins M, De Andrés J, Diwan S, Erdek M, Grigsby E, Huntoon M, Jacobs MS, Kim P, Kumar K, Leong M, Liem L, McDowell GC 2nd, Panchal S, Rauck R, Saulino M, Sitzman BT, Staats P, Stanton-Hicks M, Stearns L, Wallace M, Willis KD, Witt W, Yaksh T, Mekhail N. Polyanalgesic consensus conference – 2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation. 2012;15(5):483–95.CrossRefGoogle Scholar
  277. 277.
    Cabbell KL, Taren JA, Sagher O. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. Neurosurgery. 1998;42(5):1176–80.PubMedCrossRefGoogle Scholar
  278. 278.
    Jackson TP, Lonergan DF, Todd RD, Martin PR. Intentional intrathecal opioid detoxification in 3 patients: characterization of the intrathecal opioid withdrawal syndrome. Pain Pract. 2013;13(4):297–309.PubMedCrossRefPubMedCentralGoogle Scholar
  279. 279.
    Lee HM, Ruggoo V, Graudins A. Intrathecal clonidine pump failure causing acute withdrawal syndrome with ‘stress-induced’ cardiomyopathy. J Med Toxicol. 2016;12(1):134–8.PubMedCrossRefGoogle Scholar
  280. 280.
    Mohammed I, Hussain A. Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: a case report. BMC Clin Pharmacol. 2004;4:6.PubMedPubMedCentralCrossRefGoogle Scholar
  281. 281.
    Klimo P Jr, Kestle JR, Schmidt MH. Clinical trials and evidence-based medicine for metastatic spine disease. Neurosurg Clin N Am. 2004;15(4):549–64.PubMedCrossRefPubMedCentralGoogle Scholar
  282. 282.
    Kassamali RH, Ganeshan A, Hoey ET, Crowe PM, Douis H, Henderson J. Pain management in spinal metastases: the role of percutaneous vertebral augmentation. Ann Oncol. 2011;22(4):782–6.PubMedCrossRefPubMedCentralGoogle Scholar
  283. 283.
    Kam NM, Maingard J, Kok HK, Ranatunga D, Brooks D, Torreggiani WC, Munk PL, Lee MJ, Chandra RV, Asadi H. Combined vertebral augmentation and radiofrequency ablation in the management of spinal metastases: an update. Curr Treat Options in Oncol. 2017;18(12):74.CrossRefGoogle Scholar
  284. 284.
    Munk PL, Rashid F, Heran MK, Papirny M, Liu DM, Malfair D, Badii M, Clarkson PW. Combined cementoplasty and radiofrequency ablation in the treatment of painful neoplastic lesions of bone. J Vasc Interv Radiol. 2009;20(7):903–11.PubMedCrossRefPubMedCentralGoogle Scholar
  285. 285.
    Reyes M, Georgy M, Brook L, Ortiz O, Brook A, Agarwal V, Muto M, Manfre L, Marcia S, Georgy BA. Multicenter clinical and imaging evaluation of targeted radiofrequency ablation (t-RFA) and cement augmentation of neoplastic vertebral lesions. J Neurointerv Surg. 2018;10(2):176–82.PubMedCrossRefGoogle Scholar
  286. 286.
    Kobayashi T, Arai Y, Takeuchi Y, Nakajima Y, Shioyama Y, Sone M, Tanigawa N, Matsui O, Kadoya M, Inaba Y, Japan Interventional Radiology in Oncology Study Group (JIVROSG). Phase I/II clinical study of percutaneous vertebroplasty (PVP) as palliation for painful malignant vertebral compression fractures (PMVCF): JIVROSG-0202. Ann Oncol. 2009;20(12):1943–7.PubMedCrossRefGoogle Scholar
  287. 287.
    Berenson J, Pflugmacher R, Jarzem P, Zonder J, Schechtman K, Tillman JB, Bastian L, Ashraf T, Vrionis F, Cancer Patient Fracture Evaluation (CAFE) Investigators. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011;12(3):225–35.PubMedCrossRefGoogle Scholar
  288. 288.
    Ontario HQ. Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: an economic analysis. Ont Health Technol Assess Ser. 2016;16(12):1–34.Google Scholar
  289. 289.
    Tsoumakidou G, Too CW, Koch G, Caudrelier J, Cazzato RL, Garnon J, Gangi A. CIRSE guidelines on percutaneous vertebral augmentation. Cardiovasc Intervent Radiol. 2017;40(3):331–42.PubMedCrossRefGoogle Scholar
  290. 290.
    Chew C, Craig L, Edwards R, Moss J, O’Dwyer PJ. Safety and efficacy of percutaneous vertebroplasty in malignancy: a systematic review. Clin Radiol. 2011;66(1):63–72.PubMedCrossRefGoogle Scholar
  291. 291.
    Halpin RJ, Bendok BR, Liu JC. Minimally invasive treatments for spinal metastases: vertebroplasty, kyphoplasty, and radiofrequency ablation. J Support Oncol. 2004;2(4):339–51.PubMedGoogle Scholar
  292. 292.
    Deibert CP, Gandhoke GS, Paschel EE, Gerszten PC. A longitudinal cohort investigation of the development of symptomatic adjacent level compression fractures following balloon-assisted kyphoplasty in a series of 726 patients. Pain Physician. 2016;19(8):E1167–72.PubMedGoogle Scholar
  293. 293.
    Li G, Xue M, Chen W, Yi S. Efficacy and safety of radiofrequency ablation for lung cancers: a systematic review and meta-analysis. Eur J Radiol. 2018;100:92–8.PubMedCrossRefGoogle Scholar
  294. 294.
    Chung SR, Suh CH, Baek JH, Park HS, Choi YJ, Lee JH. Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis. Int J Hyperth. 2017;33(8):920–30.Google Scholar
  295. 295.
    Kurup AN, Morris JM, Callstrom MR. Ablation of musculoskeletal metastases. AJR Am J Roentgenol. 2017;209(4):713–21.PubMedCrossRefGoogle Scholar
  296. 296.
    Puijk RS, Ruarus AH, Scheffer HJ, Vroomen LGPH, van Tilborg AAJM, de Vries JJJ, Berger FH, van den Tol PMP, Meijerink MR. Percutaneous liver tumour ablation: image guidance, endpoint assessment, and quality control. Can Assoc Radiol J. 2018;69(1):51–62.PubMedCrossRefPubMedCentralGoogle Scholar
  297. 297.
    Maciolek KA, Abel EJ, Best SL, Emamekhoo H, Averill SL, Ziemlewicz TJ, Lubner MG, Hinshaw JL, Lee FT Jr, Wells SA. Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. Abdom Radiol (NY). 2018;43(9):2446–54.CrossRefGoogle Scholar
  298. 298.
    Yoong J, Chandra RV, William L, Franco M, Goldschlager T, Runacres F, Poon P. Percutaneous sacroplasty for painful bone metastases: a case report. Pain Pract. 2017;17(7):945–51.PubMedCrossRefPubMedCentralGoogle Scholar
  299. 299.
    Dmytriw AA, Talla K, Smith R. Percutaneous sacroplasty for the management of painful pathologic fracture in a multiple myeloma patient: case report and review of the literature. Neuroradiol J. 2017;30(1):80–3.PubMedCrossRefPubMedCentralGoogle Scholar
  300. 300.
    Cho S, Park HS, Kim DY, Kim CH, Chung RK, Kim YJ. Percutaneous sacroplasty under fluoroscopic guidance combined with epidurogram for sacral insufficiency fracture resulting from metastatic tumor and osteoporosis. Pain Physician. 2016;19(3):E473–80.PubMedPubMedCentralGoogle Scholar
  301. 301.
    Agarwal V, Sreedher G, Weiss KR, Hughes MA. Sacroplasty for symptomatic sacral hemangioma: a novel treatment approach. A case report. Interv Neuroradiol. 2013;19(2):245–9.PubMedPubMedCentralCrossRefGoogle Scholar
  302. 302.
    Moussazadeh N, Laufer I, Werner T, Krol G, Boland P, Bilsky MH, Lis E. Sacroplasty for cancer-associated insufficiency fractures. Neurosurgery. 2015;76(4):446–50.PubMedCrossRefPubMedCentralGoogle Scholar
  303. 303.
    Pereira LP, Clarençon F, Cormier E, Rose M, Jean B, Le Jean L, Chiras J. Safety and effectiveness of percutaneous sacroplasty: a single-centre experience in 58 consecutive patients with tumours or osteoporotic insufficient fractures treated under fluoroscopic guidance. Eur Radiol. 2013;23(10):2764–72.PubMedCrossRefPubMedCentralGoogle Scholar
  304. 304.
    Chai T, Suleiman ZA, Roldan CJ. Unilateral lower extremity pain due to malignancy managed with cordotomy: a case report. PMR. 2017;S1934-1482(17):31293–5.Google Scholar
  305. 305.
    Feizerfan A, Antrobus JHL. Role of percutaneous cervical cordotomy in cancer pain management. Contin Educ Anaesth Crit Care Pain. 2014;14(1):23–6.CrossRefGoogle Scholar
  306. 306.
    Kanpolat Y. The surgical treatment of chronic pain: destructive therapies in the spinal cord. Neurosurg Clin N Am. 2004;15(3):307–17.PubMedCrossRefPubMedCentralGoogle Scholar
  307. 307.
    Fitzgibbon DR. Percutaneous CT-guided C1-2 cordotomy for intractable cancer pain. Curr Pain Headache Rep. 2009;13(4):253–5.PubMedCrossRefPubMedCentralGoogle Scholar
  308. 308.
    Nashold BS Jr, el-Naggar A, Mawaffak Abdulhak M, Ovelmen-Levitt J, Cosman E. Trigeminal nucleus caudalis dorsal root entry zone: a new surgical approach. Stereotact Funct Neurosurg. 1992;59(1–4):45–51.PubMedCrossRefPubMedCentralGoogle Scholar
  309. 309.
    Kanpolat Y, Tuna H, Bozkurt M, Elhan AH. Spinal and nucleus caudalis dorsal root entry zone operations for chronic pain. Neurosurgery. 2008;62(3):235–42.. – Review of the anatomy and excellent description of the approach to stereotactic destructionPubMedPubMedCentralGoogle Scholar
  310. 310.
    Sjoquist O. Studies on pain conduction in trigeminal nerve. A contribution to the treatment of facial pain. Acta Psychiatr Neurol Suppl. 1938;17(9):139.Google Scholar
  311. 311.
    Hitchcock E. Stereotactic trigeminal tractotomy. Ann Clin Res. 1970;2(2):131–5.PubMedGoogle Scholar
  312. 312.
    Crue BL, Carregal EJA, Felsoory A. Percutaneous stereotactic radiofrequency trigeminal tractotomy with neurophysiological recordings. Stereotact Funct Neurosurg. 1972;34(6):389–97.CrossRefGoogle Scholar
  313. 313.
    Kanpolat Y, Kahilogullari G, Ugur HC, Elhan AH. Computed tomography-guided percutaneous trigeminal tractotomy-nucleotomy. Neurosurgery. 2008;63(1):147–53.Google Scholar
  314. 314.
    Sindou M, Goutelle A. Surgical posterior rhizotomies for the treatment of pain. In: Krayenbuhl H, editor. Advances and technical standards in neurosurgery, vol. 10. Vienna: Springer; 1983. p. 147–83.CrossRefGoogle Scholar
  315. 315.
    Schvarcz JR. Functional exploration of the spinomedullary junction. Acta Neurochir Suppl. 1977;24:179–85.CrossRefGoogle Scholar
  316. 316.
    Al-Chaer ED, Lawand NB, Westlund KN, Willis WD. Visceral nociceptive input into the ventral posterolateral nucleus of the thalamus: a new function for the dorsal column pathway. J Neurophysiol. 1996;76(4):2661–74.PubMedCrossRefGoogle Scholar
  317. 317.
    Shealy CN, Tyner CF, Taslitz N. Physiological evidence of bilateral spinal projections of pain fibers in cats and monkeys. J Neurosurg. 1966;24:708.PubMedCrossRefGoogle Scholar
  318. 318.
    Gildenberg PL, Hirshberg RM. Limited myelotomy for the treatment of intractable cancer pain. J Neurol Neurosurg Psychiatry. 1984;47(1):94–6.PubMedPubMedCentralCrossRefGoogle Scholar
  319. 319.
    Nauta HJ, Hewitt E, Westlund KN, Willis WD Jr. Surgical interruption of a midline dorsal column visceral pain pathway. Case report and review of the literature. J Neurosurg. 1997;86(3):538–42.PubMedCrossRefGoogle Scholar
  320. 320.
    Tonezzer T, Caffaro LAM, Menon KRS, Brandini da Silva FC, Moran de Brito CM, Sarri AJ, Casarotto RA. Effects of transcutaneous electrical nerve stimulation on chemotherapy-induced peripheral neuropathy symptoms (CIPN): a preliminary case-control study. J Phys Ther Sci. 2017;29(4):685–92.PubMedPubMedCentralCrossRefGoogle Scholar
  321. 321.
    Lee JE, Anderson CM, Perkhounkova Y, Sleeuwenhoek BM, Louison RR. Transcutaneous electrical nerve stimulation reduces resting pain in head and neck cancer patients: a randomized and placebo-controlled double-blind pilot study. Cancer Nurs. 2019;42(3):218–28.PubMedCrossRefGoogle Scholar
  322. 322.
    Loh J, Gulati A. The use of transcutaneous electrical nerve stimulation (TENS) in a major cancer center for the treatment of severe cancer-related pain and associated disability. Pain Med. 2015;16(6):1204–10.PubMedCrossRefGoogle Scholar
  323. 323.
    Loh J, Gulati A. Transcutaneous electrical nerve stimulation for treatment of sarcoma cancer pain. Pain Manag. 2013;3(3):189–99.PubMedCrossRefGoogle Scholar
  324. 324.
    Hou L, Zhou C, Wu Y, Yu Y, Hu Y. Transcutaneous electrical acupoint stimulation (TEAS) relieved cancer-related fatigue in non-small cell lung cancer (NSCLC) patients after chemotherapy. J Thorac Dis. 2017;9(7):1959–66.PubMedPubMedCentralCrossRefGoogle Scholar
  325. 325.
    Choi YD, Lee JH. Edema and pain reduction using transcutaneous electrical nerve stimulation treatment. J Phys Ther Sci. 2016;28(11):3084–7.PubMedPubMedCentralCrossRefGoogle Scholar
  326. 326.
    Hou L, Gu F, Gao G, Zhou C. Transcutaneous electrical acupoint stimulation (TEAS) ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients. J Thorac Dis. 2017;9(3):809–17.PubMedPubMedCentralCrossRefGoogle Scholar
  327. 327.
    Wong R, Major P, Sagar S. Phase 2 study of acupuncture-like transcutaneous nerve stimulation for chemotherapy-induced peripheral neuropathy. Integr Cancer Ther. 2016;15(2):153–64.PubMedPubMedCentralCrossRefGoogle Scholar
  328. 328.
    Xie J, Chen LH, Ning ZY, Zhang CY, Chen H, Chen Z, Meng ZQ, Zhu XY. Effect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced nausea and vomiting: a single-blind, randomized, controlled trial. Chin J Cancer. 2017;36(1):6.PubMedPubMedCentralCrossRefGoogle Scholar
  329. 329.
    Smith TJ, Coyne PJ, Parker GL, Dodson P, Ramakrishnan V. Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manag. 2010;40(6):883–91.CrossRefGoogle Scholar
  330. 330.
    Lee SC, Park KS, Moon JY, Kim EJ, Kim YC, Seo H, Sung JK, Lee DJ. An exploratory study on the effectiveness of “Calmare therapy” in patients with cancer-related neuropathic pain: a pilot study. Eur J Oncol Nurs. 2016;21:1–7.PubMedCrossRefPubMedCentralGoogle Scholar
  331. 331.
    Tomasello C, Pinto RM, Mennini C, Conicella E, Stoppa F, Raucci U. Scrambler therapy efficacy and safety for neuropathic pain correlated with chemotherapy-induced peripheral neuropathy in adolescents: a preliminary study. Pediatr Blood Cancer. 2018;65(7):e27064.PubMedCrossRefPubMedCentralGoogle Scholar
  332. 332.
    Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res Treat. 2016;156(3):453–64.PubMedPubMedCentralCrossRefGoogle Scholar
  333. 333.
    Hsiao HT, Chien HJ, Lin YC, Liu YC. Transcutaneous electrical nerve stimulator of 5000 Hz frequency provides better analgesia than that of 100 Hz frequency in mice muscle pain model. Kaohsiung J Med Sci. 2017;33(4):165–70.PubMedCrossRefPubMedCentralGoogle Scholar
  334. 334.
    Shealy CN, Mortimer JT, Reswick JB. Electrical inhibition of pain by stimulation of the dorsal columns: preliminary clinical report. Anesth Analg. 1967;46(4):489–91.PubMedCrossRefPubMedCentralGoogle Scholar
  335. 335.
    Peng L, Min S, Zejun Z, Wei K, Bennett MI. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. 2015;6:CD009389.Google Scholar
  336. 336.
    Xing F, Yong RJ, Kaye AD, Urman RD. Intrathecal drug delivery and spinal cord stimulation for the treatment of cancer pain. Curr Pain Headache Rep. 2018;22(2):11.PubMedCrossRefPubMedCentralGoogle Scholar
  337. 337.
    Wall PD, Sweet WH. Temporary abolition of pain in man. Science. 1967;155(3758):108–9.PubMedCrossRefPubMedCentralGoogle Scholar
  338. 338.
    Haugland M, Sinkjaer T. Interfacing the body's own sensing receptors into neural prosthesis devices. Technol Health Care. 1999;7(6):393–9.PubMedPubMedCentralGoogle Scholar
  339. 339.
    Monti E. Peripheral nerve stimulation: a percutaneous minimally invasive approach. Neuromodulation. 2004;7(3):193–6.PubMedCrossRefPubMedCentralGoogle Scholar
  340. 340.
    Slavin KV, Colpan ME, Munawar N, Wess C, Nersesyan H. Trigeminal and occipital peripheral nerve stimulation for craniofacial pain: a single-institution experience and review of the literature. Neurosurg Focus. 2006;21(6):E5.PubMedCrossRefGoogle Scholar
  341. 341.
    Huntoon MA, Burgher AH. Ultrasound-guided permanent implantation of peripheral nerve stimulation (PNS) system for neuropathic pain of the extremities: original cases and outcomes. Pain Med. 2009;10(8):1369–77.PubMedCrossRefGoogle Scholar
  342. 342.
    Deer T, Pope J, Benyamin R, Vallejo R, Friedman A, Caraway D, Staats P, Grigsby E, Porter McRoberts W, McJunkin T, Shubin R, Vahedifar P, Tavanaiepour D, Levy R, Kapural L, Mekhail N. Prospective, multicenter, randomized, double-blinded, partial crossover study to assess the safety and efficacy of the novel Neuromodulation system in the treatment of patients with chronic pain of peripheral nerve origin. Neuromodulation. 2016;19(1):91–100.PubMedCrossRefGoogle Scholar
  343. 343.
    Verrills P, Vivian D, Mitchell B, Barnard A. Peripheral nerve field stimulation for chronic pain: 100 cases and review of the literature. Pain Med. 2011;12(9):1395–405.PubMedCrossRefGoogle Scholar
  344. 344.
    Paicius RM, Bernstein CA, Lempert-Cohen C. Peripheral nerve field stimulation in chronic abdominal pain. Pain Physician. 2006;9(3):261–6.PubMedGoogle Scholar
  345. 345.
    Levi V, Messina G, Franzini A, Zanin L, Castelli N, Dones I. Peripheral nerve field stimulation (PNFS) as a treatment option for intractable radiation-induced facial neuropathic pain in a survivor of laryngeal cancer: a case report. World Neurosurg. 2016;91:671.PubMedCrossRefGoogle Scholar
  346. 346.
    US Department of Health and Human Services. 2008 physical activity guidelines for Americans. http://www.health.gov/PAGuidelines.
  347. 347.
    Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010;4(2):87–100.PubMedCrossRefGoogle Scholar
  348. 348.
    Ohira T, Schmitz KH, Ahmed RL, Yee D. Effects of weight training on quality of life in recent breast cancer survivors: the Weight Training for Breast Cancer Survivors (WTBS) study. Cancer. 2006;106(9):2076–83.PubMedCrossRefGoogle Scholar
  349. 349.
    Espíndula RC, Nadas GB, Rosa MID, Foster C, Araújo FC, Grande AJ. Pilates for breast cancer: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2017;63(11):1006–12.CrossRefGoogle Scholar
  350. 350.
    Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;8:CD008465.Google Scholar
  351. 351.
    Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018;1:CD011292.PubMedPubMedCentralGoogle Scholar
  352. 352.
    Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, Snyder C. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;8:CD007566.Google Scholar
  353. 353.
    Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvão DA. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16(4):328–35.PubMedCrossRefPubMedCentralGoogle Scholar
  354. 354.
    Galvão DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38(12):2045–52.PubMedCrossRefPubMedCentralGoogle Scholar
  355. 355.
    Al-Majid S, Waters H. The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise. Biol Res Nurs. 2008;10(1):7–20.PubMedCrossRefPubMedCentralGoogle Scholar
  356. 356.
    Kang DW, Lee EY, An KY, Min J, Jeon JY, Courneya KS. Associations between physical activity and comorbidities in Korean cancer survivors. J Cancer Surviv. 2018;12(4):441–9.PubMedCrossRefPubMedCentralGoogle Scholar
  357. 357.
    Schmitz KH, Speck RM. Risks and benefits of physical activity among breast cancer survivors who have completed treatment. Womens Health (Lond). 2010;6(2):221–38.CrossRefGoogle Scholar
  358. 358.
    Nelson NL. Breast cancer-related lymphedema and resistance exercise: a systematic review. J Strength Cond Res. 2016;30(9):2656–65.PubMedCrossRefPubMedCentralGoogle Scholar
  359. 359.
    Ruiz JR, Sui X, Lobelo F, Lee DC, Morrow JR Jr, Jackson AW, Hébert JR, Matthews CE, Sjöström M, Blair SN. Muscular strength and adiposity as predictors of adulthood cancer mortality in men. Cancer Epidemiol Biomark Prev. 2009;18(5):1468–76.CrossRefGoogle Scholar
  360. 360.
    Markes M, Brockow T, Resch KL. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 2006;4:CD005001.Google Scholar
  361. 361.
    Furmaniak AC, Menig M, Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 2016;9:CD005001.PubMedPubMedCentralGoogle Scholar
  362. 362.
    Ottenbacher A, Yu M, Moser RP, Phillips SM, Alfano C, Perna FM. Population estimates of meeting strength training and aerobic guidelines, by gender and cancer survivorship status: findings from the Health Information National Trends Survey (HINTS). J Phys Act Health. 2015;12(5):675–9.PubMedCrossRefPubMedCentralGoogle Scholar
  363. 363.
    Bourke L, Homer KE, Thaha MA, Steed L, Rosario DJ, Robb KA, Saxton JM, Taylor SJ. Interventions for promoting habitual exercise in people living with and beyond cancer. Cochrane Database Syst Rev. 2013;9:CD010192.Google Scholar
  364. 364.
    Andersen C, Rorth M, Ejlertsen B, Adamsen L. Exercise despite pain--breast cancer patient experiences of muscle and joint pain during adjuvant chemotherapy and concurrent participation in an exercise intervention. Eur J Cancer Care (Engl). 2014;23(5):653–67.CrossRefGoogle Scholar
  365. 365.
    Sheill G, Guinan E, Neill LO, Hevey D, Hussey J. The views of patients with metastatic prostate cancer towards physical activity: a qualitative exploration. Support Care Cancer. 2018;26(6):1747–54.PubMedCrossRefPubMedCentralGoogle Scholar
  366. 366.
    Jensen BT, Jensen JB, Laustsen S, Petersen AK, Søndergaard I, Borre M. Multidisciplinary rehabilitation can impact on health-related quality of life outcome in radical cystectomy: secondary reported outcome of a randomized controlled trial. J Multidiscip Healthc. 2014;7:301–11.PubMedPubMedCentralCrossRefGoogle Scholar
  367. 367.
    Mirandola D, Miccinesi G, Muraca MG, Belardi S, Giuggioli R, Sgambati E, Manetti M, Monaci M, Marini M. Longitudinal assessment of the impact of adapted physical activity on upper limb disability and quality of life in breast cancer survivors from an Italian cohort. Support Care Cancer. 2018;26(2):329–32.PubMedCrossRefPubMedCentralGoogle Scholar
  368. 368.
    Jensen BT, Petersen AK, Jensen JB, Laustsen S, Borre M. Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: a prospective randomized controlled trial. Scand J Urol. 2015;49(2):133–41.PubMedCrossRefPubMedCentralGoogle Scholar
  369. 369.
    Cho Y, Do J, Jung S, Kwon O, Jeon JY. Effects of a physical therapy program combined with manual lymphatic drainage on shoulder function, quality of life, lymphedema incidence, and pain in breast cancer patients with axillary web syndrome following axillary dissection. Support Care Cancer. 2016;24(5):2047–57.PubMedCrossRefPubMedCentralGoogle Scholar
  370. 370.
    Cheville AL, Rhudy L, Basford JR, Griffin JM, Flores AM. How receptive are patients with late stage cancer to rehabilitation services and what are the sources of their resistance? Arch Phys Med Rehabil. 2017;98(2):203–10.PubMedCrossRefPubMedCentralGoogle Scholar
  371. 371.
    Nishigori H, Ishii M, Kokado Y, Fujimoto K, Higashiyama H. Effectiveness of pelvic floor rehabilitation for bowel dysfunction after intersphincteric resection for lower rectal cancer. World J Surg. 2018;42(10):3415–21.PubMedCrossRefPubMedCentralGoogle Scholar
  372. 372.
    Chen SC, Huang BS, Chung CY, Lin CY, Fan KH, Chang JT, Wu SC. Effects of a swallowing exercise education program on dysphagia-specific health-related quality of life in oral cavity cancer patients post-treatment: a randomized controlled trial. Support Care Cancer. 2018;26(8):2919–28.PubMedCrossRefPubMedCentralGoogle Scholar
  373. 373.
    Maher C, Mendonca RJ. Impact of an activity-based program on health, quality of life, and occupational performance of women diagnosed with cancer. Am J Occup Ther. 2018;72(2):1–8.CrossRefGoogle Scholar
  374. 374.
    Ferrer RA, Huedo-Medina TB, Johnson BT, Ryan S, Pescatello LS. Exercise interventions for cancer survivors: a meta-analysis of quality of life outcomes. Ann Behav Med. 2011;41(1):32–47.PubMedPubMedCentralCrossRefGoogle Scholar
  375. 375.
    Rick O, Dauelsberg T, Kalusche-Bontemps EM. Oncological rehabilitation. Oncol Res Treat. 2017;40(12):772–7.PubMedCrossRefGoogle Scholar
  376. 376.
    De Groef A, Van Kampen M, Vervloesem N, Dieltjens E, Christiaens MR, Neven P, Vos L, De Vrieze T, Geraerts I, Devoogdt N. Effect of myofascial techniques for treatment of persistent arm pain after breast cancer treatment: randomized controlled trial. Clin Rehabil. 2018;32(4):451–61.PubMedCrossRefGoogle Scholar
  377. 377.
    De Groef A, Van Kampen M, Vervloesem N, De Geyter S, Christiaens MR, Neven P, Vos L, De Vrieze T, Geraerts I, Devoogdt N. Myofascial techniques have no additional beneficial effects to a standard physical therapy programme for upper limb pain after breast cancer surgery: a randomized controlled trial. Clin Rehabil. 2017;31(12):1625–35.PubMedCrossRefGoogle Scholar
  378. 378.
    Baxter GD, Liu L, Petrich S, Gisselman AS, Chapple C, Anders JJ, Tumilty S. Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review. BMC Cancer. 2017;17(1):833.PubMedPubMedCentralCrossRefGoogle Scholar
  379. 379.
    Castro-Martín E, Ortiz-Comino L, Gallart-Aragón T, Esteban-Moreno B, Arroyo-Morales M, Galiano-Castillo N. Myofascial induction effects on neck-shoulder pain in breast cancer survivors: randomized, single-blind, placebo-controlled crossover design. Arch Phys Med Rehabil. 2017;98(5):832–40.PubMedCrossRefGoogle Scholar
  380. 380.
    Imperatori A, Grande A, Castiglioni M, Gasperini L, Faini A, Spampatti S, Nardecchia E, Terzaghi L, Dominioni L, Rotolo N. Chest pain control with kinesiology taping after lobectomy for lung cancer: initial results of a randomized placebo-controlled study. Interact Cardiovasc Thorac Surg. 2016;23(2):223–30.PubMedCrossRefGoogle Scholar
  381. 381.
    Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ. 2005;330(7493):702.PubMedPubMedCentralCrossRefGoogle Scholar
  382. 382.
    Tighe M, Molassiotis A, Morris J, Richardson J. Coping, meaning and symptom experience: a narrative approach to the overwhelming impacts of breast cancer in the first year following diagnosis. Eur J Oncol Nurs. 2011;15(3):226–32.PubMedCrossRefGoogle Scholar
  383. 383.
    Jazzar U, Yong S, Klaassen Z, Huo J, Hughes BD, Esparza E, Mehta HB, Kim SP, Tyler DS, Freedland SJ, Kamat AM, Wolf DV, Williams SB. Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer. 2018;124(15):3127–35.PubMedCrossRefGoogle Scholar
  384. 384.
    Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer. 2009;115(22):5349–61.PubMedCrossRefGoogle Scholar
  385. 385.
    Barber B, Dergousoff J, Slater L, Harris J, O'Connell D, El-Hakim H, Biron VL, Mitchell N, Seikaly H. Depression and survival in patients with head and neck cancer: a systematic review. JAMA Otolaryngol Head Neck Surg. 2016;142(3):284–8.PubMedCrossRefGoogle Scholar
  386. 386.
    Lattie EG, Antoni MH, Millon T, Kamp J, Walker MR. MBMD coping styles and psychiatric indicators and response to a multidisciplinary pain treatment program. J Clin Psychol Med Settings. 2013;20(4):515–25.PubMedCrossRefGoogle Scholar
  387. 387.
    Holmes A, Christelis N, Arnold C. Depression and chronic pain. Med J Aust. 2013;199(6 Suppl):S17–20.PubMedGoogle Scholar
  388. 388.
    Turk DC, Fillingim RB, Ohrbach R, Patel KV. Assessment of psychosocial and functional impact of chronic pain. J Pain. 2016;17(9 Suppl):T21–49.PubMedCrossRefGoogle Scholar
  389. 389.
    Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry. 1993;50(9):681–9.PubMedCrossRefGoogle Scholar
  390. 390.
    Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2(8668):888–91.PubMedCrossRefGoogle Scholar
  391. 391.
    Xia Y, Tong G, Feng R, Chai J, Cheng J, Wang D. Psychosocial and behavioral interventions and cancer patient survival again: hints of an adjusted meta-analysis. Integr Cancer Ther. 2014;13(4):301–9.PubMedCrossRefGoogle Scholar
  392. 392.
    Giese-Davis J, Collie K, Rancourt KMS, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29(4):413–20.PubMedCrossRefGoogle Scholar
  393. 393.
    Mulick A, Walker J, Puntis S, Burke K, Symeonides S, Gourley C, Wanat M, Frost C, Sharpe M. Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials. Lancet Psychiatry. 2018;5(4):321–6.PubMedCrossRefGoogle Scholar
  394. 394.
    Dobson K, Dozios DJA. Historical and philosophical bases of the cognitive behavioral therapy. In: Dobson KS, editor. Handbook of cognitive behavioral therapies. 3rd ed. New York, NY: Guilford Press; 2010. p. 3–38.Google Scholar
  395. 395.
    Folkman S, Moskowitz JT. Stress, positive emotion, and coping. Cur Dir Psych Sci. 2000;9(4):115–8.CrossRefGoogle Scholar
  396. 396.
    McGinn L, Sanderson W. What allows cognitive behavioral therapy to be brief: overview, efficacy and crucial factors facilitating brief treatment. Psychol Sci Pract. 2001;8(1):23–37.CrossRefGoogle Scholar
  397. 397.
    Dalton JA, Keefe FJ, Carlson J, Youngblood R. Tailoring cognitive-behavioral treatment for cancer pain. Pain Manag Nurs. 2004;5(1):3–18.PubMedCrossRefGoogle Scholar
  398. 398.
    Anderson KO, Cohen MZ, Mendoza TR, Guo H, Harle MT, Cleeland CS. Brief cognitive-behavioral audiotape interventions for cancer-related pain: immediate but not long-term effectiveness. Cancer. 2006;107(1):207–14.PubMedCrossRefGoogle Scholar
  399. 399.
    Kwekkeboom KL, Abbott-Anderson K, Cherwin C, Roiland R, Serlin RC, Ward SE. Pilot randomized controlled trial of a patient-controlled cognitive-behavioral intervention for the pain, fatigue, and sleep disturbance symptom cluster in cancer. J Pain Symptom Manag. 2012;44(6):810–22.CrossRefGoogle Scholar
  400. 400.
    Phianmongkhol Y, Thongubon K, Woottiluk P. Effectiveness of cognitive behavioral therapy techniques for control of pain in lung cancer patients: an integrated review. Asian Pac J Cancer Prev. 2015;16(14):6033–8603.PubMedCrossRefPubMedCentralGoogle Scholar
  401. 401.
    Chiesa A, Serretti A. Mindfulness-based interventions for chronic pain: a systematic review of the evidence. J Altern Complement Med. 2011;17(1):83–93.PubMedCrossRefPubMedCentralGoogle Scholar
  402. 402.
    Reiner K, Tibi L, Lipsitz JD. Do mindfulness-based interventions reduce pain intensity? A critical review of the literature. Pain Med. 2013;14(2):230–42.PubMedCrossRefPubMedCentralGoogle Scholar
  403. 403.
    Johannsen M, O'Connor M, O'Toole MS, Jensen AB, Hojris I, Zachariae R. Efficacy of mindfulness-based cognitive therapy on late post-treatment pain in women treated for primary breast cancer: a randomized controlled trial. J Clin Oncol. 2016;34(28):3390–9.PubMedCrossRefPubMedCentralGoogle Scholar
  404. 404.
    Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982;4(1):33–47.PubMedCrossRefPubMedCentralGoogle Scholar
  405. 405.
    Baer RA, Carmody J, Hunsinger M. Weekly change in mindfulness and perceived stress in a mindfulness-based stress reduction program. J Clin Psychol. 2012;68(7):755–65.PubMedCrossRefPubMedCentralGoogle Scholar
  406. 406.
    Elvery N, Jensen MP, Ehde DM, Day MA. Pain catastrophizing, mindfulness, and pain acceptance: what’s the difference? Clin J Pain. 2017;33(6):485–95.PubMedCrossRefPubMedCentralGoogle Scholar
  407. 407.
    Turner JA, Anderson ML, Balderson BH, Cook AJ, Sherman KJ, Cherkin DC. Mindfulness-based stress reduction and cognitive behavioral therapy for chronic low back pain: similar effects on mindfulness, catastrophizing, self-efficacy, and acceptance in a randomized controlled trial. Pain. 2016;157(11):2434–44.PubMedPubMedCentralCrossRefGoogle Scholar
  408. 408.
    Johannsen M, O'Connor M, O'Toole MS, Jensen AB, Zachariae R. Mindfulness-based cognitive therapy and persistent pain in women treated for primary breast cancer: exploring possible statistical mediators: results from a randomized controlled trial. Clin J Pain. 2018;34(1):59–67.PubMedPubMedCentralGoogle Scholar
  409. 409.
    Reich RR, Lengacher CA, Alinat CB, Kip KE, Paterson C, Ramesar S, Han HS, Ismail-Khan R, Johnson-Mallard V, Moscoso M, Budhrani-Shani P, Shivers S, Cox CE, Goodman M, Park J. Mindfulness-based stress reduction in post-treatment breast cancer patients: immediate and sustained effects across multiple symptom clusters. J Pain Symptom Manag. 2017;53(1):85–95.CrossRefGoogle Scholar
  410. 410.
    National Center for Complementary and Integrative Health. Complementary, Alternative, or Integrative Health: What’s In a Name? nccam.nih.gov/health/whatiscam.
  411. 411.
    Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick SM, Boyce LM, Tripathy D. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194–232.PubMedPubMedCentralCrossRefGoogle Scholar
  412. 412.
    Armstrong K, Lanni T Jr, Anderson MM, Patricolo GE. Integrative medicine and the oncology patient: options and benefits. Support Care Cancer. 2018;26(7):2267–73.PubMedCrossRefPubMedCentralGoogle Scholar
  413. 413.
    Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, Mumber M, Perlmutter J, Seely D, Sen A, Zick SM, Tripathy D, Society for Integrative Oncology. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014;2014(50):346–58.PubMedPubMedCentralCrossRefGoogle Scholar
  414. 414.
    US Preventive Services Task Force. Grade definitions; 2008. http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm.
  415. 415.
    Shen Y, Liu L, Chiang JS, Meng Z, Garcia MK, Chen Z, Peng H, Bei W, Zhao Q, Spelman AR, Cohen L. Randomized, placebo-controlled trial of K1 acupoint acustimulation to prevent cisplatin-induced or oxaliplatin-induced nausea. Cancer. 2015;121(1):84–92.PubMedCrossRefPubMedCentralGoogle Scholar
  416. 416.
    Gan TJ, Jiao KR, Zenn M, Georgiade G. A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting. Anesth Analg. 2004;99(4):1070–5.PubMedCrossRefPubMedCentralGoogle Scholar
  417. 417.
    Bao T, Cai L, Giles JT, Gould J, Tarpinian K, Betts K, Medeiros M, Jeter S, Tait N, Chumsri S, Armstrong DK, Tan M, Folkerd E, Dowsett M, Singh H, Tkaczuk K, Stearns V. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast Cancer Res Treat. 2013;138(1):167–74.PubMedPubMedCentralCrossRefGoogle Scholar
  418. 418.
    Crew KD, Capodice JL, Greenlee H, Apollo A, Jacobson JS, Raptis G, Blozie K, Sierra A, Hershman DL. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. J Cancer Surviv. 2007;1(4):283–91.PubMedCrossRefPubMedCentralGoogle Scholar
  419. 419.
    Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W, Hershman DL. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010;28(7):1154–60.PubMedCrossRefPubMedCentralGoogle Scholar
  420. 420.
    Oh B, Kimble B, Costa DS, Davis E, McLean A, Orme K, Beith J. Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study. Acupunct Med. 2013;31(3):264–71.PubMedCrossRefPubMedCentralGoogle Scholar
  421. 421.
    Mao JJ, Farrar JT, Bruner D, Zee J, Bowman M, Seluzicki C, DeMichele A, Xie SX. Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial. Cancer. 2014;120(23):3744–51.PubMedPubMedCentralCrossRefGoogle Scholar
  422. 422.
    Paley CA, Johnson MI, Tashani OA, Bagnall AM. Acupuncture for cancer pain in adults. Cochrane Database Syst Rev. 2015;(10):CD007753.Google Scholar
  423. 423.
    Hu C, Zhang H, Wu W, Yu W, Li Y, Bai J, Luo B, Li S. Acupuncture for pain management in cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2016;2016:1720239.PubMedPubMedCentralGoogle Scholar
  424. 424.
    Melchart D, Weidenhammer W, Streng A, Reitmayr S, Hoppe A, Ernst E, Linde K. Prospective investigation of adverse effects of acupuncture in 97,733 patients. Arch Intern Med. 2004;164(1):104–5.PubMedCrossRefPubMedCentralGoogle Scholar
  425. 425.
    Witt CM, Pach D, Brinkhaus B, Wruck K, Tag B, Mank S, Willich SN. Safety of acupuncture: results of a prospective observational study with 229,230 patients and introduction of a medical information and consent form. Forsch Komplementmed. 2009;16(2):91–7.PubMedPubMedCentralGoogle Scholar
  426. 426.
    Healing Touch Program. What Is Healing Touch? https://www.healingtouchprogram.com/about/what-is-healing-touch.
  427. 427.
    Post-White J, Kinney ME, Savik K, Gau JB, Wilcox C, Lerner I. Therapeutic massage and healing touch improve symptoms in cancer. Integr Cancer Ther. 2003;2(4):332–44.PubMedCrossRefPubMedCentralGoogle Scholar
  428. 428.
    McGilvery C, Reed J. Step-by-step massage: a guide to massage techniques for health, relaxation and vitality. Detroit, MI: Treasure Press; 1994.Google Scholar
  429. 429.
    Hughes D, Ladas E, Rooney D, Kelly K. Massage therapy as a supportive care intervention for children with cancer. Oncol Nurs Forum. 2008;35(3):431–42.PubMedCrossRefPubMedCentralGoogle Scholar
  430. 430.
    Billhult A, Lindholm C, Gunnarsson R, Stener-Victorin E. The effect of massage on immune function and stress in women with breast cancer--a randomized controlled trial. Auton Neurosci. 2009;150(1–2):111–5.PubMedCrossRefGoogle Scholar
  431. 431.
    Lee PL, Tam KW, Yeh ML, Wu WW. Acupoint stimulation, massage therapy and expressive writing for breast cancer: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2016;27:87–101.PubMedCrossRefGoogle Scholar
  432. 432.
    Foley NC, Bhogal SK, Teasell RW, Bureau Y, Speechley MR. Estimates of quality and reliability with the physiotherapy evidence-based database scale to assess the methodology of randomized controlled trials of pharmacological and nonpharmacological interventions. Phys Ther. 2006;86(6):817–24.PubMedGoogle Scholar
  433. 433.
    Shin ES, Seo KH, Lee SH, Jang JE, Jung YM, Kim MJ, Yeon JY. Massage with or without aromatherapy for symptom relief in people with cancer. Cochrane Database Syst Rev. 2016;(6):CD009873.Google Scholar
  434. 434.
    Izgu N, Ozdemir L, Bugdayci Basal F. Effect of aromatherapy massage on chemotherapy-induced peripheral neuropathic pain and fatigue in patients receiving oxaliplatin: an open label quasi-randomized controlled pilot study. Cancer Nurs. 2019;42(2):139–47.PubMedCrossRefGoogle Scholar
  435. 435.
    Lopez G, Liu W, Milbury K, Spelman A, Wei Q, Bruera E, Cohen L. The effects of oncology massage on symptom self-report for cancer patients and their caregivers. Support Care Cancer. 2017;25(12):3645–50.PubMedCrossRefGoogle Scholar
  436. 436.
    Jane SW, Chen SL, Wilkie DJ, Lin YC, Foreman SW, Beaton RD, Fan JY, Lu MY, Wang YY, Lin YH, Liao MN. Effects of massage on pain, mood status, relaxation, and sleep in Taiwanese patients with metastatic bone pain: a randomized clinical trial. Pain. 2011;152(10):2432–42.PubMedCrossRefGoogle Scholar
  437. 437.
    Wilcock A, Manderson C, Weller R, Walker G, Carr D, Carey AM, Broadhurst D, Mew J, Ernst E. Does aromatherapy massage benefit patients with cancer attending a specialist palliative care day centre? Palliat Med. 2004;18(4):287–90.PubMedCrossRefGoogle Scholar
  438. 438.
    National Center for Complementary and Integrative Health. Yoga. nccih.nih.gov/health/yoga.
  439. 439.
    Smith KB, Pukall CF. An evidence-based review of yoga as a complementary intervention for patients with cancer. Psychooncology. 2009;18(5):465–75.PubMedCrossRefGoogle Scholar
  440. 440.
    Buffart LM, van Uffelen JG, Riphagen II, Brug J, van Mechelen W, Brown WJ, Chinapaw MJ. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2012;12:559.PubMedPubMedCentralCrossRefGoogle Scholar
  441. 441.
    Wayne PM, Lee MS, Novakowski J, Osypiuk K, Ligibel J, Carlson LE, Song R. Tai Chi and Qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis. J Cancer Surviv. 2018;12(2):256–67.PubMedCrossRefGoogle Scholar
  442. 442.
    Danhauer SC, Addington EL, Sohl SJ, Chaoul A, Cohen L. Review of yoga therapy during cancer treatment. Support Care Cancer. 2017;25(4):1357–72.PubMedPubMedCentralCrossRefGoogle Scholar
  443. 443.
    Carlson LE, Zelinski E, Toivonen K, Flynn M, Qureshi M, Piedalue KA, Grant R. Mind-body therapies in cancer: what is the latest evidence? Curr Oncol Rep. 2017;19(10):67.PubMedCrossRefGoogle Scholar
  444. 444.
    Derry HM, Jaremka LM, Bennett JM, Peng J, Andridge R, Shapiro C, Malarkey WB, Emery CF, Layman R, Mrozek E, Glaser R, Kiecolt-Glaser JK. Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial. Psychooncology. 2015;24(8):958–66.PubMedCrossRefGoogle Scholar
  445. 445.
    Littman AJ, Bertram LC, Ceballos R, Ulrich CM, Ramaprasad J, McGregor B, McTiernan A. Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures. Support Care Cancer. 2012;20(2):267–77.PubMedCrossRefGoogle Scholar
  446. 446.
    Cohen L, Warneke C, Fouladi RT, Rodriguez MA, Chaoul-Reich A. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer. 2004;100(10):2253–60.PubMedCrossRefGoogle Scholar
  447. 447.
    Peppone LJ, Janelsins MC, Kamen C, Mohile SG, Sprod LK, Gewandter JS, Kirshner JJ, Gaur R, Ruzich J, Esparaz BT, Mustian KM. The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy. Breast Cancer Res Treat. 2015;150(3):597–604.PubMedPubMedCentralCrossRefGoogle Scholar
  448. 448.
    Adair M, Murphy B, Yarlagadda S, Deng J, Dietrich MS, Ridner SH. Feasibility and preliminary efficacy of tailored yoga in survivors of head and neck cancer: a pilot study. Integr Cancer Ther. 2018;17(3):774–84.PubMedPubMedCentralCrossRefGoogle Scholar
  449. 449.
    Cramer H, Ward L, Saper R, Fishbein D, Dobos G, Lauche R. The safety of yoga: a systematic review and meta-analysis of randomized controlled trials. Am J Epidemiol. 2015;182(4):281–93.PubMedCrossRefGoogle Scholar
  450. 450.
    Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 2017;1:CD010802.PubMedPubMedCentralGoogle Scholar
  451. 451.
    Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL, Malarkey WB, Emery CF, Layman R, Mrozek EE, Glaser R. Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2014;32(10):1040–9.PubMedPubMedCentralCrossRefGoogle Scholar
  452. 452.
    Mustian KM, Sprod LK, Janelsins M, Peppone LJ, Palesh OG, Chandwani K, Reddy PS, Melnik MK, Heckler C, Morrow GR. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol. 2013;31(26):3233–41.PubMedPubMedCentralCrossRefGoogle Scholar
  453. 453.
    Bower JE, Garet D, Sternlieb B, Ganz PA, Irwin MR, Olmstead R, Greendale G. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial. Cancer. 2012;118(15):3766–75.PubMedCrossRefPubMedCentralGoogle Scholar
  454. 454.
    Potié A, Roelants F, Pospiech A, Momeni M, Watremez C. Hypnosis in the perioperative management of breast cancer surgery: clinical benefits and potential implications. Anesthesiol Res Pract. 2016;2016:2942416.PubMedPubMedCentralGoogle Scholar
  455. 455.
    National Cancer Institute. Topics in Integrative, Alternative, and Complementary Therapies (PDQ)-Patient Version. cancer.gov/about-cancer/treatment/cam/patient/cam-topics-pdq.
  456. 456.
    Taylor S, Harley C, Ziegler L, Brown J, Velikova G. Interventions for sexual problems following treatment for breast cancer: a systematic review. Breast Cancer Res Treat. 2011;130(3):711–24.PubMedCrossRefPubMedCentralGoogle Scholar
  457. 457.
    Del Casale A, Ferracuti S, Rapinesi C, Serata D, Caltagirone SS, Savoja V, Piacentino D, Callovini G, Manfredi G, Sani G, Kotzalidis GD, Girardi P. Pain perception and hypnosis: findings from recent functional neuroimaging studies. Int J Clin Exp Hypn. 2015;63(2):144–70.PubMedCrossRefPubMedCentralGoogle Scholar
  458. 458.
    Adachi T, Fujino H, Nakae A, Mashimo T, Sasaki J. A meta-analysis of hypnosis for chronic pain problems: a comparison between hypnosis, standard care, and other psychological interventions. Int J Clin Exp Hypn. 2014;62(1):1–28.PubMedCrossRefPubMedCentralGoogle Scholar
  459. 459.
    Montgomery GH, David D, Kangas M, Green S, Sucala M, Bovbjerg DH, Hallquist MN, Schnur JB. Randomized controlled trial of a cognitive-behavioral therapy plus hypnosis intervention to control fatigue in patients undergoing radiotherapy for breast cancer. J Clin Oncol. 2014;32(6):557–63.PubMedPubMedCentralCrossRefGoogle Scholar
  460. 460.
    Jensen MP. Hypnosis for chronic pain management: a new hope. Pain. 2009;146(3):235–7.PubMedCrossRefPubMedCentralGoogle Scholar
  461. 461.
    Montgomery GH, Bovbjerg DH, Schnur JB, David D, Goldfarb A, Weltz CR, Schechter C, Graff-Zivin J, Tatrow K, Price DD, Silverstein JH. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. J Natl Cancer Inst. 2007;99(17):1304–12.PubMedCrossRefGoogle Scholar
  462. 462.
    Montgomery GH, Kangas M, David D, Hallquist MN, Green S, Bovbjerg DH, Schnur JB. Fatigue during breast cancer radiotherapy: an initial randomized study of cognitive-behavioral therapy plus hypnosis. Health Psychol. 2009;28(3):317–22.PubMedCrossRefGoogle Scholar
  463. 463.
    Wortzel J, Spiegel D. Hypnosis in cancer care. Am J Clin Hypn. 2017;60(1):4–17.PubMedCrossRefGoogle Scholar
  464. 464.
    Montgomery GH, Weltz CR, Seltz M, Bovbjerg DH. Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients. Int J Clin Exp Hypn. 2002;50(1):17–32.PubMedCrossRefGoogle Scholar
  465. 465.
    Lahoud MJ, Kourie HR, Antoun J, El Osta L, Ghosn M. Road map for pain management in pancreatic cancer: a review. World J Gastrointest Oncol. 2016;8(8):599–606.PubMedPubMedCentralCrossRefGoogle Scholar
  466. 466.
    Mendoza ME, Capafons A, Gralow JR, Syrjala KL, Suárez-Rodríguez JM, Fann JR, Jensen MP. Randomized controlled trial of the Valencia model of waking hypnosis plus CBT for pain, fatigue, and sleep management in patients with cancer and cancer survivors. Psychooncology. 2017;26(11):1832–8.PubMedCrossRefGoogle Scholar
  467. 467.
    Brugnoli MP, Pesce G, Pasin E, Basile MF, Tamburin S, Polati E. The role of clinical hypnosis and self-hypnosis to relief pain and anxiety in severe chronic diseases in palliative care: a 2-year long-term follow-up of treatment in a nonrandomized clinical trial. Ann Palliat Med. 2018;7(1):17–31.PubMedCrossRefGoogle Scholar
  468. 468.
    Berlière M, Roelants F, Watremez C, Docquier MA, Piette N, Lamerant S, Megevand V, Van Maanen A, Piette P, Gerday A, Duhoux FP. The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy. Breast. 2018;37:114–8.PubMedCrossRefGoogle Scholar
  469. 469.
    Jochimsen PR, Lawton RL, VerSteeg K, Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther. 1978;24(2):223–7.PubMedCrossRefGoogle Scholar
  470. 470.
    Compton WM, Han B, Hughes A, Jones CM, Blanco C. Use of marijuana for medical purposes among adults in the United States. JAMA. 2017;317(2):209–11.PubMedCrossRefPubMedCentralGoogle Scholar
  471. 471.
    Pergam SA, Woodfield MC, Lee CM, Cheng GS, Baker KK, Marquis SR, Fann JR. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. 2017;123(22):4488–97.PubMedPubMedCentralCrossRefGoogle Scholar
  472. 472.
    Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73.PubMedCrossRefPubMedCentralGoogle Scholar
  473. 473.
    Kramer JL. Medical marijuana for cancer. CA Cancer J Clin. 2015;65(2):109–22.PubMedPubMedCentralCrossRefGoogle Scholar
  474. 474.
    Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, Chow E, O'Hearn S. A selective review of medical cannabis in cancer pain management. Ann Palliat Med. 2017;6(Suppl 2):S215–22.PubMedCrossRefPubMedCentralGoogle Scholar
  475. 475.
    Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17(6):739–44.PubMedCrossRefPubMedCentralGoogle Scholar
  476. 476.
    Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, Sacks HS. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16(12):1221–32.PubMedPubMedCentralCrossRefGoogle Scholar
  477. 477.
    Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag. 2010;39(2):167–79.CrossRefGoogle Scholar
  478. 478.
    Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49.PubMedCrossRefPubMedCentralGoogle Scholar
  479. 479.
    Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Kornyeyeva E, Fallon MT. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manag. 2018;55(2):179–88.CrossRefGoogle Scholar
  480. 480.
    Zhang MW, Ho RC. The cannabis dilemma: a review of its associated risks and clinical efficacy. J Addict. 2015;2015:707596.PubMedPubMedCentralCrossRefGoogle Scholar
  481. 481.
    Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975;15(2–3):139–43.PubMedCrossRefPubMedCentralGoogle Scholar
  482. 482.
    Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manag. 2014;47(1):166–73.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Jonathan Silverman
    • 1
  • Amitabh Gulati
    • 2
  1. 1.Department of AnesthesiologyWeill-Cornell Medical CenterNew YorkUSA
  2. 2.Department of Anesthesiology and Critical Care MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations